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ABSTRACT 
 
 MICROBIOLOGICAL PROFILE OF LOWER GENITAL TRACT 
INFECTIONS IN WOMEN OF REPRODUCTIVE AGE GROUP WITH SPECIAL 
REFERENCE TO CHLAMYDIA TRACHOMATIS BY REALTIME PCR 
ASSAYIN A TERTIARY CARE HOSPITAL 
Background and Aims: 
 Lower genital tract infections are the major cause of gynecological morbidity and a 
great public health concern in India. Inadequate laboratory diagnostic facilities in all the 
levels of health care,  stigma and discrimination associated with RTI services are some of 
the reasons of lack of exact incidence/prevalence rate of RTI in India.  Hence this study is 
conducted to assess the microbiological profile of lower genital tract infections in women 
of reproductive age group with special reference to Chlamydia trachomatis by Real Time 
PCR assay in a tertiary care hospital 
Methodology:  
 Women with symptoms suggestive of lower genital tract infections were selected 
and vaginal swab, endocervical swab and 5ml blood sample were collected after obtaining 
detailed history and informed consent from the patient. Vaginal swab was used for 
evaluation by Gram staining and culture for bacterial and fungal pathogens. Endocervical 
swab  was  subjected  to  culture  for  Neisseria  gonorrhea  and  Real  time  PCR  analysis  of  
Chlamydia trachomatis. The serum sample was subjected to analysis for HBV, HCV, HIV, 
HSV and syphilis.. 
Results: 
 Out of 110 subjects, 43 subjects (39.09%) were identified with laboratory findings 
for lower genital tract infections. 18.75% of Chlamydia trachomatis was identified by Real 
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time PCR assay. Factors such as women with age  30 years, parity belonging to L2 group 
and IUCD users were seem to have significant influence in the outcome. 
Conclusion: 
 Laboratory diagnosis for women with symptoms and signs is suggested when 
compared to syndromic approach. Screening for sexually transmitted infections by 
serological  methods  are  mandatory  in  women  with  symptoms  and  signs  of  genital  tract  
infections. 
Keywords: 
 Lower genital tract infections, Chlamydia trachomatis, Real time PCR, 
Reproductive tract infections (RTI) 
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1 
INTRODUCTION 
  
 Lower genital tract infectionsare the major cause of gynecological morbidity and a 
great public health concern in India. The infections affecting the lower genital tract 
includes sexually transmitted diseases such as Chlamydia, Gonorrhea, Trichomoniasis, 
Syphilis, endogenous infections such as vulvovaginal candidiasis or bacterial vaginosis and 
iatrogenic infections which are associated with medical procedures. (1) 
In developing nation like India, genital tract infections are the most common 
problem which adds physical and mental burden among the women of reproductive age 
group. The response of Government and society to genital tract infections is more 
influenced by the stigma towards sexual behavior than the degree of distress caused by the 
illness. WHO statistics indicate that the total number of new cases ofReproductive Tract 
Infections (RTI) in adults between the ages of 15 and 49 was estimated to be 498.9million 
including lower genital tract infections. Among them are 105.7 million cases of Chlamydia 
trachomatis, 106.1 million cases of Neisseria gonorrhoeae and 276.4 million cases of 
Trichomonasvaginalis. (2) 
Community prevalence study conductedin India showed that 5% to 6% of sexually 
active adult populations are suffering from RTI.(3) The  common  causes  of  lower  genital  
tract infections areChlamydia trachomatis, Candidiasis, Trichomoniasis, Bacterial 
vaginosis, Gonorrhea, Syphilis, Human papilloma virus(HPV) infection, Herpes simplex 
virus(HSV) infectionand other bacterial infections.(4) 
A study conducted at Regional STD teaching and training centre, New Delhi 
figures out that 19.9% of the study group were infected with Chlamydia trachomatis.(5) In 
females, the asymptomatic Chlamydial infection, if left untreated leads to Pelvic 
Inflammatory Disease (PID), infertility and its complications. Henceforth, screening 
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women forChlamydia trachomatis helps  in  prevention  of  PID,  ectopic  pregnancy  and  
infertility. Nucleic acid amplification technique like Polymerase chain reaction increased 
the chance of diagnosing and reporting Chlamydia trachomatis infection  over  those  of  
culture and other serological tests. 
Likewise, a similar study conducted at New Delhi estimated that 9.4% of the study 
group was infected with candidiasis, 7.8% with bacterial vaginosis, 1.8% with syphilis, 1% 
with Trichomoniasis, 0.7% with gonorrhea and 0.3% with chancroid.(5)   This implies that 
screening for lower genital tract infections by laboratory methods is advisory before giving 
empirical treatment. 
Individuals suffering from RTI have significantly increased chance of acquiring 
and transmitting Human Immunodeficieny Virus (HIV), Hepatitis B virus (HBV), 
Hepatitis C virus (HCV).  Hence screening for HIV, HbsAg and HCV is mandatory for all 
cases with complaints suggestive of RTI.(6) 
The  low level  of  awareness  among women is  because  of  stigma and  it  adds  up  a  
major contribution factor for the increase in the incidence of genital tract infections.  
Inadequate laboratory diagnostic facilities in all the levels of health care, limited resources 
in material and manpower, stigma and discrimination associated with RTI services are 
some of the reasons of lack of exact incidence/prevalence rate of RTI in India, which forms 
an important data tool for determining intervention and treatment strategies.(7)Moreover, 
epidemiological studies in RTI are not abundant in south India.(8)Hence this study is 
conducted to provide a reliable laboratory based data on the microbiological profile of 
lower genital tract infections. 
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AIMS AND OBJECTIVES 
 
1. To study the various socio demographic profiles associated with lower genital tract 
infections in women of reproductive age group. 
2. To isolate and to study the microbiological profile of lower genital tract infection in 
women of reproductive age group. 
3. To determine the proportion of Chlamydia trachomatis among the study group by 
Real-time PCR assay. 
4. To  study  the  co  infections  caused  by  HBV,  HCV,  HSV,  HIV  and  Syphilis  by  
various serological methods. 
 
 
 
 
 
 
 
 
 

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REVIEW OF LITERATURE 

 Genital tract infections are most commonly caused by various organisms which 
include bacteria, viruses, parasites and fungi. They are transmitted by vaginal, anal and 
oral sexual contact. Some organisms also spreads through other modes like blood 
transfusion, skin abrasions that add on more threat. E.g. HBV, HCV, HIV, HSV and 
Syphilis. Lower genital tract infections are the leading cause of morbidity in both 
developing and developed countries, which increases the psychological stress in the young 
sexually active females. WHO estimates that more than 1 million people acquire RTI 
everyday.(9) 
Background: 
 The normal vaginal epithelium is an important immune lining which helps in 
preventing many infections. Vaginal cells contain glycogen and it is continually shed in the 
lumen of the vagina. The normal microbial flora of vagina has predominantly 
Lactobacillus crispatus and Lactobacillus jensenii.(10) The  glycogen  is  depolymerized  to  
glucose and utilized by the lactobacilli which on metabolism results in the production of 
lactic acid. This is responsible for the acidic pH of the normal vagina (3.5 to 4.5) providing 
immunity against pathogens (Eg:gonorrhea).(11) In addition, Lactobacilli produce hydrogen 
peroxide which is highly bactericidal. The normal vaginal flora is altered because of 
exposure to sexually transmitted pathogens or due to overgrowth of endogenous 
organisms.(12)  The differential diagnosis of a patient presenting with discharge per 
vaginum includes trichomoniasis, vulvo-vaginal candidiasis, bacterial vaginosis, 
desquamative inflammatory vaginitis, cervicitis and vulvovaginitis associated with 
oestrogendeficiency. 
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Epidemiology of Genital tract infections: 
 Epidemiological data based on previous studies show that the incidence and 
prevalence of RTI vary greatly between countries, which are influenced by the differences 
in the characteristics of each pathogen as well as other biological, behavioral, medical, 
social, and economic factors.(13)  It was estimated that in developing countries, gonorrhea 
rates  are  10–15  times  higher,  the  rates  of  Chlamydia  are  2–3  times  higher,  and  syphilis  
rates are 10–100 times higher than the rates among women in industrialized countries.(14) 
However, because of dissimilarities in study design, specimen collection, and laboratory 
methods across the world, it is difficult to compare and interpret the data on prevalence of 
RTIs. Still, the data that are available suggest that RTI are common in almost all of the 
developing nations, with high prevalence rates among commercial sex workers and clients 
of STD clinics.(15) 
 According to WHO, an estimated 499 million new cases of curable infections like 
Gonorrheae, Chlamydia, Syphilis and Trichomoniasis occur each year, 536 million people 
have incurable HSV-2 infection and 291 million women have HPV infection.(16)NACO 
estimates that 3 crore episodes of RTI occurs per year.(17)Several studies have been 
conducted in India to estimate the prevalence of RTI, but the stigma and culture of silence 
among women in rural areas, the exact data cannot be estimated.  A systematic review by 
aarthiet al., have found that there are only 41 eligible studies on estimation of prevalence 
of RTI. The above study also states that the prevalence of self reported reproductive tract 
infections  is  11  to  72%,  whereas  it  is  7  to  34%  in  the  studies  where  laboratory  methods  
were used to confirm clinical diagnosis.(18) Hence at situations possible, it is important to 
support the clinical diagnosis by laboratory based proven diagnosis in all STD centres. 
 In India, NACP- Phase IV has focused on prevention strategies by condom 
promotion, targeted interventions for high risk groups and blood safety and prevention and 
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control of RTI. In 2013-2014, 67.7 lakhs people with RTI were managed as per national 
protocol.(19) 
Mode of Transmission of genital tract infections: 
 Generally, the agents causing lower genital tract infections enter the body through 
the mucosal lining due to unprotected sexual intercourse with an infected partner. Most of 
the infections that are sexually transmitted exhibit “biological sexism” i.e., the anatomical 
factors make the transmission of infections in higher rate from male to female.(20)Infections 
occur in women earlier and more severely than men. Women have less ability to get 
prevention from RTI because of their  social  conditions,  lack of female condoms and also 
due to larger surface area exposed during intercourse. For instance, in gonorrhea, the risk 
of getting infection is 25% for men but for women it is 50%.(21) 
Factors affecting the spread of genital tract infections in a population: 
x Biological factors which include the infectivity of the pathogen, duration of 
infectivity, presence of co-infections, age and immunological status of the 
individual. 
x Behavioral factors like type of sexual intercourse, number of sexual partners, use of 
contraceptives. 
x Medical factors like accessibility to health care facilities, accessibility of laboratory 
facilities and availability of appropriate treatment. 
x Social and Economic factors like religion, education status, income, occupation and 
migration. 
Etiological agents causing lower genital tract infections: 
 Lower genital tract infections are caused by various bacteria, viruses, parasites and 
fungi. The most common among them are discussed as follows: 
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GENITAL CHLAMYDIASIS: 
 Chlamydia was first observed in the year 1907, in a conjuctival epithelial cell 
scrapings obtained from an orang-utan, which has been inoculated with the material from a 
trachoma infected patient. Chlamydiae are obligate intracellular bacterial pathogen. The 
genus Chlamydia has three species, Chlamydia trachomatis, Chlamydia psittaci and 
Chlamydia pneumoniae. Chlamydia trachomatis has 15 serologic variants. Serotypes D to 
K are mostly associated with urethritis, cervicitis, endometritis, salpingitis, infertility, 
repeated abortions. Joy et al., found 30.8% of STD clinic patients were reported with 
Chlamydia trachomatis.(21) Another study conducted in Punjab, India states that anti-
Chlamydial antibodies were present in 68% of women with infertility and 50% of women 
with bad obstetric history.(22) Many other studies from India have estimated the prevalence 
of C. trachomatis infection to be 23% in gynecology outpatient department (OPD) and 
19.9 per cent in STD clinics.(23) 
 Chlamydia trachomatis presents as asymptomatic infection and hence if left 
untreated it leads to PID and infertility. Centre for Disease Control and Prevention has 
recommended screening of women for C.trachomatis under the age of 24 years, at least 
once in a year.(24) In our country screening is not being done due to lack of exact 
prevalence  data  and  adequate  resources.  There  is  no  study  on  the  prevalence  of  
C.trachomatis from Chengalpattu, a semi-urban area and hence this study is conducted to 
generate an evidence of infection in this area. 
Morphology: 
 Chlamydiae  possess  both  DNA  and  RNA  and  they  have  cell  wall.  An  unique  
feature of the species in Chlamydiae is their complex reproductive cycle. There are two 
forms in the developmental cycle namely elementary body(EB) and reticulate body(RB). 
The EB is the infective form transmitted from one person to another. EBs gets attached to 
the target cells and then enter the cells inside a phagosome. Within 8 hrs of entry into the 
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cell,  the EBs gets converted into RBs and gets adapted to intracellular survival and starts 
its multiplication. They undergo binary fission and produces enormous replicates within 
the intracellular membrane body called as inclusion body. After 24 h, the RB gets 
converted to EB and the inclusion then lyses, releasing EBs from the cell. 
Laboratory diagnosis: 
 The endocervix is the preferred site of specimen collection. Endocervical swabs are 
collected under sterile precautions and immediately stored in the transport medium (-
20degC). Studies have shown that 10-20% increase in the recovery of Chlamydia 
trachomatis has been observed if both cervical and urethral specimens are taken when 
compared to cervical swab alone.(25) 
Direct Microscopic Examination: 
 Chlamydial inclusion bodies can be seen in direct microscopic examination. It is 
readily stained by Giemsa or Papanicolaou stains. These methods require expert 
interpretation, not sensitive, helpful only for examination of conjunctival smears and 
unsuitable for genital smears.  
Culture: 
 As the organism is intracellular, it can be isolated only in living cells. Cell lines 
helpful  for  the  growth  of  Chlamydiae  are  McCoy(Mouse  fibroblast  line),  HeLa  229(  
Human  cervical  carcinoma),  BHK  21(Baby  hamster  kidney).  Cell  culture  is  difficult  to  
perform and therefore done in laboratories where research process with quality control are 
being ensured. The sensitivity of the cell culture varies from 70 to 85% depends on the 
laboratory and the specificity is 100%.(26) 
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Immunoassays: 
 Commercially available tests for the rapid detection of Chlamydial antigen have 
improved the management of sexually transmitted Chlamydial infection. Enzyme 
Immunoassay and Immunofluorescence are the two widely used methods.  Serological 
tests are not routinely done for the diagnosis of uncomplicated genital  infections and it  is  
not recommended for the screening of asymptomatic individuals. The sensitivity of 
enzyme immunoassay is 62 to 96 per cent and specificity is of 86 to 99 per cent in 
comparison to cell culture.(27)It is suitable for laboratories where cell culture cannot be 
performed. However,  multiple studies across the world including India have reported that  
there is poor sensitivity of ELISA in comparison to PCR.Abida Malik et al., reported that 
the sensitivity and specificity of ELISA in detection of C.trachomatis was 48% and 92.9% 
respectively.(28) 
Molecular methods: 
 The gold standard test for diagnosing Chlamydia trachomatis infection is the 
detection of nucleic acid in samples i.e.,  Nucleic Acid Amplification Test(NAAT).(29)The 
most common are the Amplicor CT/NG test for both Chlamydia trachomatis and Neisseria 
gonorrheae and CobasAmplicor Chlamydia trachomatis, Genprobe, BD probe. 
Endocervical specimens are marginally more sensitive than urine in women but urine is 
more  sensitive  than  urethral  swabs  in  asymptomatic  men.  The  true  specificity  of  NAAT  
test  is  99  %.(30) The exact chlamydial load in the genital tract can be detected by 
quantitative real-time PCR and can vary from 10 to over a million organisms/ml of the 
discharge.  This  has  a  role  in  the  interpretation  of  test  results  where  there  is  no  
differentiation between the people with high and low Chlamydia loads in the performance 
of different nucleic acid amplification tests. The Chlamydial load has an impact with the 
clinical symptoms, the transmissibility of infection, and the risk of developing chronicity, 
therefore the role of quantification in the diagnosis is important. 
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Treatment: 
 Tetracycline 500mg four times daily for a period of seven days or single 1gm dose 
of azithromycin is equally effective. Till now, no drug resistance has been reported. 
CANDIDIASIS: 
First known description of oral Candidiasis was found in the writings of 
Hippocrates and Galen. Since then, the incidence of Candida infections affecting various 
systems of the body has risen abruptly. Vulvovaginal candidiasis is characterized clinically 
by pruritis, pain, curdy white vaginal discharge. It is more common in pregnancy, diabetes 
mellitus and patients on chronic antibiotic therapy. Some workers have estimated that 75% 
of adult females will get atleast one single episode of vulvovaginal candidiasis during their 
lifetime.(31) In India, only two community based studies have been conducted in which 
laboratory-confirmed vulvovaginal candidiasis had been reported. Bang et al. diagnosed 
vulvovaginal candidiasis in 35% ,out of 650 reproductive age group women living in 
Maharashtra, and Prasad et al. diagnosed vulvovaginal candidiasis in 10% , out of 451 
married women in Tamil Nadu.(32,33) 
Morphology:  
 Candida are yeast like fungi, small, thin walled Gram positive ovoid cells with 
pseudohyphae that reproduces by budding. Till date, there are 163 anamorphic species of 
Candida but among them, twenty are considered to be significant pathogens. 
Laboratory diagnosis: 
 The difficulty in diagnosis Candida as a pathogen is due to the colonization in the 
body sites. Candida sp., can be a part of the normal vaginal flora of an asymptomatic 
women.  Hence the isolation of organism in culture should be correlated well with the 
clinical symptoms and signs. 
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Direct Microscopy: 
 Saline  wet  mount  and  10%  KOH  mount  helps  in  detecting  yeast  cells.  On  direct  
Gram staining, Gram positive budding yeast cells and presence of pseudohyphae can be 
visualized. The presence of pseudohyphae in the direct smear indicates tissue invasion 
rather than colonization. Calcoflour white staining can also be used to visualize and to 
increase the chance of identifying the fungal elements. 
Fungal Culture:  
 The most common media used for isolating Candida is Sabourards dextrose agar 
(SDA). The media is inoculated and incubated at 37degC. Within 3 to 4 days, creamy 
coloured, smooth and pasty colonies are visualized.  
Species identification:  
1. Germ tube test  – a colony of the cultured candida is  treated with sheep or normal 
human serum and incubated at 37°C for 2 hours. The germ tube formation will be 
seen in Candida albicans and Candida dublinensis. 
2. Sugar fermentation and assimilation test 
3. Chlamydospore formation – the culture is streaked in a cornmeal agar or ricestarch 
agar  with  a  coverslip  overlay  and  incubated  at  25°C;  it  shows  large,  highly  
refractile, thick walled, terminal chlamydospores after 2 to 3 days of incubation. 
4. CHROMagar  Candida  –  CHROMagar  is  a  rapid,  plate  based  test  for  the  
identification of candida species based on the morphology and colour production. 
Immunodiagnosis: 
 The serological tests which are used currently lack specificity and sensitivity. 
Antigen based tests to detect cell wall mannan or cytoplasmic components are mainly used 
in the serodiagnosis of systemic candidiasis. 
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Treatment: 
 The azole creams like clotrimazole, miconazole, ketoconazole are applied locally 
for the mucocutaneous lesions. Nystatin is used as suspension of 2,00,000 units/ml for the 
resistant mucosal lesions. Amphotericin B is given for the systemic lesions as intravenous 
infusion 
 Nowdays, the non albicans Candida sp.,  are in rise of causing infections and they 
pose a threat by being resistant to antifungal drugs. Hence it is advised to perform 
antifungal susceptibility testing as per the Clinical Laboratory Standard Institute (CLSI) 
guidelines M27-A to promptly treat these infections. 
TRICHOMONIASIS: 
 Trichomoniasis is caused by the protozoan Trichomonasvaginalis. It was first 
observed by Donne in 1836 from the purulent genital discharge of a female. The organism 
is not a colonizer and transmission almost always occurs through sexual contact. It is 
mostly asymptomatic and if symptomatic they present with complaints of vaginal 
discharge which are copious, yellow green frothy discharge, vulvar irritation, dysuria, 
dyspareunia and abnormal fishy vaginal odour. On speculum examination, punctuate 
mucosal hemorrhages of the cervix gives ‘strawberry vagina’ appearance. In a study 
conducted by Madhivannan et al., 2005, out of 898 participated women, 8.5% had 
Trichomoniasis.(34) 
Morphology: 
 Trichomonas belongs to the family Trichomonadidae. It is a genital flagellate 
protozoan.  It  differs  from  the  other  flagellates  as  they  lack  the  cystic  stage.  Only  
trophozoite stage exits. It is a pear shaped, motile organism residing in the vagina and 
urethra of women and urethra, seminal vesicle and prostate of men. It bears five flagella – 
four  anterior  flagella  and  one  lateral  flagella.  The  axostyle  runs  down  the  middle  of  the  
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trophozoite and ends in the posterior pole. It has a single nucleus with a central karyosome. 
It binds to the vaginal epithelium by the enzymes secreted by the trophozoites like 
adhesions, proteolytic enzymes and erythrocyte binding proteins etc., 
Laboratory diagnosis: 
Microscopy: 
 Identification is by examination of wet mount of vaginal and urethral discharges. 
Chance of isolation is more if there is multiple and repeated sampling.  
 Saline wet mount - The discharge collected and diluted with a drop of saline and 
examined for motile organism under low power with reduced illumination. The jerky 
movement  of  motile  trophozoites  and  pus  cells  can  be  seen  which  has  the  sensitivity  of  
approximately 60%.   
 Permanent Stain – Giemsa stain and Papanicolaou stain are helpful to demonstrate 
the  morphology  of  trophozoites.Acridine  Orange(AO)  fluorescent  stain  –  rapid  and  
sensitive when compared to wet mount. The sensitivity and specificity of AO staining 
method is 52% and 98% respectively (S.Mirrettet al.,)(35) 
Culture : 
 Culture is the gold standard method for the diagnosis of Trichomoniasis. Culture 
has a higher sensitivity than wet mount of 75-85% and a specificity of 100%. (36)Specimen 
should be processed and inoculated immediately. Various culture media used are Lash’s 
cyteinehydrolysate serum media, Diamond`s trypticase yeast maltose media, csyteine 
peptone liver maltose media. Kupferberg`s STS medium ,Modified Diamond medium is 
the most sensitive culture method. Cultures should be incubated for a period of 3 to 7 days 
or even longer. Wet mount should be prepared from the culture to demonstrate the motile 
trophozoites. 
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 In a study conducted by Razia et al.,(2015), different methods for the laboratory 
diagnosis of Trichomonasvaginalis was compared. The sensitivity of saline wet mount was 
58.8%, when compared with culture as gold standard. 8.1% (out of 835 patients)were 
found to be positive for trichomoniasis by culture in Kupferberg medium.(37) Although, 
culture is considered gold standard for the diagnosis, but laboratory facilities for culture are 
not available at all places. There is a delay in the diagnosis, as it takes 2 to 7 days for the 
culture and thus it may lead to loss of follow up of patient.  
Immunological assays: 
  Antigen detection in the vaginal secretion is more sensitive than 
microscopy. A rapid dipstick test based on the principle of immunochromatography is 
available with result in 10 minutes and sensitivity of 83% and specificity of 99%.(38) 
ELISA detecting Trichomonial antigen is also available with a sensitivity of 89% and 
specificity of 97%. (39) ELISA detecting antibody is not useful as antibodies persist for 
longer time and it is difficult to differentiate between the current and past infection. 
Molecular methods:   
 The highly sensitive method is molecular testing like Polymerase Chain Reaction 
using T.vaginalis specific beta tubulin genes. 
Miscellaneous tests: 
Vaginal pH analysis: 
 Vaginal pH is raised. But it is not specific as it is also raised in bacterial vaginosis. 
Whiff test (Amine test): 
 When a drop of 10% KOH is added to the frothy vaginal discharge, the fishy odour 
is accentuated due to the production of amine. It is also positive in bacterial vaginosis. In 
more than 75% cases of trichomoniasis, the whiff test is positive.(40) 
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Treatment: 
 The drug of choice is Metronidazole 2g, single dose or a 7 days course of 500mg 
bd. The expected cure rate is 90%.  Treatment should be given to both the sexual partners. 
Resistance to metronidazole is rare but it has been reported. Safe sexual practices like use 
of condoms till infection gets cleared is advised. 
BACTERIAL VAGINOSIS: 
 Bacterial vaginosis (BV)  is caused by abnormal growth of bacteria in the vaginal 
flora  with  the  replacement  of  normal  indigenous  microbial  flora.  This  condition  was  first  
described  by  Gardner  and  Dukes  in  the  year  1955.   It  is  the  leading  cause  of  RTI  
accounting for about 48% of cases.(41) The predisposing factors for the bacterial vaginosis 
are having multiple sexual partners, when having a new sexual partner or when doing 
repeated douching. The clinical presentations are homogenous thin vaginal discharge with 
fishy odour and lower abdomen pain. The labia and vulva are not erythematous or 
oedematous like candidiasis or trichomoniasis. The causative agents for bacterial vaginosis 
are Gardnerellavaginalis, Mobiluncus spp., Peptostreptococci, Prevotella and 
Porphyromonas.(42) It is usually a polymicrobial infection. Vaginal pH gets altered as the 
normal lactobacilli are being depleted by the overgrowth of abnormal pathogens in 
bacterial vaginosis.  
Gardnerella is a normal microbial flora which on excess proliferation causes 
Gardnerellavaginalis infection. It acts as a predisposing factor for miscarriages and preterm 
deliveries. There is also increased risk of endometritis and salpingitis among women with 
BV.(43) 
Bacterial vaginosis is a major public health concern in India and research studies on 
BV are low when compared to other RTI studies.  Madhivannan et al,(2005) reported that 
19.1% of women were infected with bacterial vaginosis in his study and Bhalla P et 
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all.,(2007) reported that 32.8% were infected with bacterial vaginosis in his population. 
(44,45)With limited resource laboratories like in rural areas, the diagnosis of bacterial 
vaginosis is challenging and there is a need for point of care tests. 
Laboratory diagnosis: 
A wet mount prepared from the vaginal discharge usually reveals clue cells, which 
are the vaginal epithelial cells studded with coccobacilli. In almost 90% of the cases, clue 
cells are visible. The clue cell was named by Herman Gardner because they provided a 
clue to the diagnosis of this condition.  The sensitivity and specificity of clue cells  in wet 
mount is 81% and 99%, provided the count of clue cells should be more than 20% 
.(46)Diagnosis  of  Bacterial  vaginosis  was  first  done  by  Amsel  et  al.,  and  he  formulated  a  
criteria to distinguish the non specific vaginitis from the BV. (47)The diagnostic criterion of 
Amsel is as follows: 
x Homogenous vaginal discharge 
x Whiff test positive  
x Clue cells  
x Vaginal pH > 4.5 
(At least presence of three out of these four criteria is enough to make the diagnosis of BV) 
 Another criteria which is based on direct Gram staining alone with scoring system 
was devised by Nugent et al. He made scoring system ranged from 0 to 10 based on the 
following tabulation criteria.  The sensitivity and specificity is 90% and 94% 
respectively.(48) Nugent scoring is mainly based on observer skill and knowledge. 
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NUGENT SCORING 
Lactobacilli Score Gardnerella, Bacteroides Score 
Curved 
GNB Score Sum 
 30 0 0 0 0 0 0 
5 – 30 1 < 1 1 < 1 1 3 
1 – 4 2 1 – 4 2 1 – 4 1 5 
< 1 3 5 – 30 3 5 – 30 2 8 
0 4  30 4  30 2 10 
 
INTERPRETATION OF NUGENT SCORE 
Score (N) Additional criteria Report 
0 – 3  
Smear not consistent with 
Bacterial Vaginosis 
4 – 6 When clue cells are not present 
4 – 6 When clue cells are present 
Smear consistent with 
Bacterial Vaginosis 
 7  
 
Treatment:  
 The  drug  regimen for  treating  BV is  oral  metronidazole  500mg twice  a  day  for  a  
period of 7 days. Vaginal preparations with 0.75% metronidazole gel or 2% clindamycin 
cream are also effective. For patients who is not responding to the antimicrobial drugs, 
intravaginal boric acid 600mg at bedtime gives symptomatic relief. Pregnant women with 
BV should be treated with oral metronidazole or oral clindamycin. Topical agents is not 
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advised for pregnant females as it has adverse effects like prematurity. There is no protocol 
to give treatment for the male sexual partners and hence it is not recommended.   
GONORRHEA: 
 In 1879, Neisser discovered the bacterium gonococcus and it was then proven as 
the causative agent of gonorrhea. Gonorrhea is a sexually transmitted infection that has its 
history  since  medieval  period.  British  parliament  has  enacted  a  law  in  the  year  1611  to  
ensure the spread of infection as it was a major public health problem then. It was initially 
called as clap as the infected person experienced a clapping sensation during micturition. 
Later it was renamed after the discovery of causative agent, Neisseria gonorrhea. The 
incidence of gonococcal infections has declined significantly worldwide, yet in developing 
countries it still remains a public health problem. The exact surveillance data is difficult to 
assess because of variable diagnostic criteria.  Studies conducted in Africa showed that non 
ulcerative STI like gonorrhea are an independent risk factor in the transmission of HIV 
when compared to ulcerative STI. In 2003, it was second to Chlamydia trachomatis among 
the STI`s in the United States, with 335,104 cases of gonorrhea reported.(49) But the 
prevalence of gonorrhea has been declining. In a study conducted by Prasad et al., at rural 
Tamil Nadu,(2005) there was no laboratory diagnosed case of gonococcal infection.(50) 
Morphology: 
Neisseria gonorrhoeae is a gram negative diplococci, non motile, non sporingcocci, 
kidney shaped with concave surface facing each other. It is catalase positive, oxidase 
positive. It ferments glucose but not maltose, sucrose or lactose. It has proteins, 
lipooligosaccharides and phospholipids in its outer membrane. Pili mediatesgonococcal 
attachment to the columnar epithelial cells. Another surface protein helpful in the 
adherence is the Opa – Opacity associated protein.  
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 In addition to the antigenic structures, host factors are also important in the 
pathogenesis of infection. Activation of phosphatidyl choline – specific phospholipase C 
and  sphingomyelinase  by  the  organism  resulting  in  the  release  of  ceramide  and  
diacylglycerol, paves a way for the entry of N.gonorrhoeae into the epithelial cells. The 
patient presents with cervicitis, urethritis, proctitis and conjunctivitis. It can also spreads to 
local sites causing complications like salpingitis, endometritis and tuboovarian abscess, 
epididymitis in males. Disseminated gonococcemia is rare. 
Laboratory diagnosis: 
Direct Microscopy: 
Gram staining of urethral exudates from men or endocervical swab for women 
shows gram negative intracellular diplococcic which is highly specific and sensitive in 
diagnosing gonococcal urethritis. But it is only 50% sensitive in diagnosing gonococcal 
cervicitis. Polymorphonuclear cells are seen in the Gram stain in an abnormally elevated 
number which gives a clue to the diagnosis. Sood et al.,(2009) figured out that direct 
microscopic technique is best with symptomatic men giving high sensitivity of 
approximately 95% and  specificity of 99%. (51) 
Culture: 
The culture of gonococci is quite difficult in basal media. Endocervical swab 
should be collected with Dacron or rayon or charcoal impregnated swabs. As gonococci is 
highly susceptible to drying ,  temperature or toxic substances like cotton swabs,  it  should 
be inoculated immediately in a selective medium like Modified Thayer Martin medium. If 
plates cannot be incubated immediately, it can be kept in room temperature upto six hours 
provided  it  is  inside  the  candle  extinction  jars.  The  organism  needs  CO2  for  its  growth.  
The isolate is confirmed with biochemical reactions and any gonococci isolated should be 
tested for antimicrobial susceptibility testing according to CLSI guidelines.  
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Culture is the "Gold Standard" for the definitive diagnosis of gonorrhoea. The 
sensitivity of culture is 85í95% in case of acute infection and the specificity is 100%, 
whereas in chronic infections it is 50% sensitivity.(52) Although, the gonococcal culture 
methods are well described, there are certain disadvantages in practical usage. They are 
specimen transports, fastidiousness of the organism, and laboratory techniques. In addition, 
multiple steps like transport medium, method of inoculation and optimal conditions of 
incubation are necessary for the processing of specimens, and hence the quality assurance 
varies with the laboratory performance. Also, at least 48-72 hours is needed for culture and 
thereby resulting in delays in diagnosis and treatment.  
Molecular methods: 
In the recent years, nucleic acid probe tests are widely in use for the direct detection 
of N.gonorrhoeae in urogenital specimens. NAATs include Roche Amplicor,Gen-Probe 
APTIMA Combo2 (detects Chlamydia trachomatis also) and BD ProbeTec ET. When 
compared with NAATs, gonoccocal culture has sensitivity from 85 to 95% for acute 
infections and may become as low as 50% for females with chronic infection.(53) 
Treatment: 
 Single dose regimens of Ceftriaxone and Cefixime are the mainstays of treatment 
modality for uncomplicated gonococcal infection of genitourinary system. Since co 
infection with Chlamydia trachomatis is common, the treatment regimen should include a 
single 2gm dose of azithromycin also.  
SYPHILIS: 
 Syphilis, caused by Treponemapallidum subsp., pallidum is a sexually transmitted 
infection causing a chronic systemic disease. T.pallidum can penetrate the intact mucous 
membrane or through the minute abrasions in the skin and enters the lymphatics and blood.  
It has three stages of clinical presentation. In primary syphilis, single painless chancre 
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(hard chancre) appears in the genital region. After 1 to 3 months of the occurrence of 
primary lesion, secondary syphilis stage starts. Due to rapid multiplication of the 
spirochaetes, it disseminates through the blood and the patient may presents with 
meningeal, ocular, osseous or gastrointestinal involvement. In tertiary stage, cardiovascular 
and neurological involvement like tabesdorsalis, general paralysis of insane occurs. 
Eventhough the advent of penicillin therapy has significantly reduced the incidence of 
syphilis, it still remains as a global health problem. The number of new infections 
occurring globally is estimated at nearly 12 million per year. Arpita et al., found that 
among 570 cases attended the STI clinic from the year 2005 to 2009, 42 (7.36%) cases 
were found to have syphilis. (54) 
 The causative agent of syphilis, Treponemapallidum, was discovered in the year 
1905 by Schaudinn and Hoffmann. The word pallidum refers to the pale staining nature of 
syphilis. It is a thin, delicate spirochaete which is of size about 10µm× 0.1 to 0.2µm with 
ten  regular  spirals.  It  is  actively  motile  with   rotator  movement  around  the  long  axis  and  
backward and forward movement and flexion of the body. 
Laboratory diagnosis: 
 The lesions are highly infectious. Hence care must be obtained while collecting the 
specimens from the lesions. The lesion is gently scraped and gently pressure is given to the 
undersurface of the lesion and the exudates are collected. Serum samples have to be 
collected for serological evaluation. 
Direct Microscopy: 
 Wet  films  are  prepared  from  the  exudates  and  it  is  examined  under  dark  ground  
illumination. T.pallidum is identified by its slender spiral structure and its slow motility. A 
concentration of 104 /ml in the exudates is needed to visualize the T.pallidum in  a  wet  
mount. Silver impregnation staining technique can also be used.  
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Direct fluorescent antibody test for T.Pallidum(DFA  –  TP)  :  Smears  from  the  infective  
lesions is fixed with acetone. DFA-TP test is done using the fluorescent tagged anti 
T.pallidum antiserum.  
 The direct microscopic techniques become positive one to three weeks before 
serological test and are most useful in the diagnosis of primary, secondary and early 
congenital syphilis. 
Serological test: 
 Non Specific Tests include Venereal Disease Research Laboratory (VDRL)/ Rapid 
Plasma Reagin (RPR) test. These tests use the cardiolipin antigen extracted from beef heart 
with  added  lecithin  and  cholesterol.  These  tests  are  recommended  for  screening  as  they  
give  rapid  results.  The  sensitivity  of   VDRL  in  diagnosing  Primary  syphilis  is  78%,  
secondary syphilis is100%, latent syphilis is 95%, late syphilis is 71% (55). The specificity 
of  the  test  is  98  to  100%.  Specific  tests  for  T.pallidum includes 
TreponemaPallidumImmobilisation(TPI), Fluorescent treponemal antibody(FTA) test, 
Treponemapallidumhemagglutination  assay(TPHA)  and  Enzyme  immunoassays.  TPI  test  
is  the  gold  standard  test  and  FTA-ABS  is  the  standard  reference  test.  The  sensitivity  of  
TPHA is 85 to 100% and the specificity is 98 to 100%.(56) 
Treatment: 
 Benzathine penicillin G - 2.4mU i.m single dose is given in primary and secondary 
stages of syphilis. In patients with history of allergy to penicillin, Tetracycline HCl – 
500mg qid or doxycycline – 100mg bd can be given. In tertiary stage with neurosyphilis, 
aqueous crystalline penicillin G 18 to 24mU/d IV is given. 
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HERPES SIMPLEX VIRUS: 
Herpes Simplex Virus (HSV) is a linear double stranded DNA virus. It produces a 
wide variety of infections which involve the local mucocutaneous surfaces causing painful 
lesions to systemic manifestations affecting central nervous system and sometimes visceral 
organs. Exposure to HSV through oral or genital sexual contact permits the entry of the 
virus through the skin abrasions or minor trauma. The virus then enters the epidermal cells 
and multiplies rapidly. First episode herpetic lesions presents with fever, pain, itching, 
painful micturition, discharge per vaginum and associated inguinal lymphadenopathy. But 
the presentation is usually subclinical. Then it enters to the sensory or autonomic nerve 
endings like trigeminal ganglia in case of HSV I and sacral  nerve root ganglia in case of 
HSV II and remains latent. Virus then spreads to other mucocutaneous surfaces and there 
is increased frequency of new lesions with primary genital and orolabial HSV infection. 
Once infected the patient presents subclinical infection and later recurrent infections are 
more common when the immune condition of the patient gets altered. 
 Infection with HSV I is acquired more frequently than HSV II. The major problem 
with HSV II infections are unidentified carrier state which acts as a source of threat by 
silent transmission of infection. The frequent reactivation of the latent stage of the virus 
from the genital tract led to continuous spread of virus throughout the world. Study 
conducted at JIPMER, India by Devinder et al., found that 115 (85.1%) were seropositive 
for HSV-2 from a total sample size of 135.(57) Pregnant women with genital herpes lead to 
preterm delivery, neonate with HSV meningitis and septicemia. International studies have 
found that 1:3200 children born have neonatal herpetic infection every year. (58) 
Laboratory diagnosis: 
Direct Microcopy: 
 The base of the genital  lesion is  scraped off and the smear is  stained with Giemsa 
or Toluidine blue stain. The smear reveals multinucleated giant cells with intra nuclear 
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inclusion called Cowdry type A bodies. When electron microscopy is available, the 
diagnosis is fast and reliable. From the fluid exudates from vesicle, the virions are visible 
in electron microscopy and it is easy to interpret. The diagnosis can be made within an 
hour of specimen collection.  
Virus isolation: 
 Scrapings or Swabs collected and transported in a suitable condition are inoculated 
in the cell culture lines like human diploid fibroblast lines, Vero cell lines and cytopathic 
effects  can  be  seen  as  early  as  16  hours  with  a  median  time  of  2  to  3  days.  Almost  95% 
cases can be diagnosed within a period of seven days, but the cultures should not be 
discarded until  14 days.  The main advantage of viral  culture is  the detection of even low 
titres of virus. 
Serology:  
 IgM Antibodies to HSV infections occurs in 4 to 7 days after infection and reaches 
a peak in 2 to 4 weeks. It can be detected by neutralization tests, immunofluorescent 
technique and Enzyme linked Immunosorbent Assay (ELISA). The drawback of 
serological tests is IgG antibodies persist for lifelong with fluctuations and it is helpful 
only for research purposes. Recently developed type specific IgG ELISA detects HSV 
antibodies accurately with no cross reactivity. The sensitivity and specificity of the tests 
varies from 95% to 99%.(59) 
Molecular methods: 
 Polymerase Chain Reaction method is sensitive and specific in the diagnosis.  It  is  
the widely used method for diagnosis of HSV meningitis. According to Slomka MJ et al., 
the sensitivity of PCR vs Cell culture is 80.9%, whereas the specificity is 100%.(60) 
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Treatment: 
 Acyclovir (200mg 5 times/day or 400mg tid) is the drug of choice for genital 
herpetic lesions. It is a nucleoside analog which inhibits the viral DNA synthesis. The drug 
suppresses the severity of the clinical manifestations and it reduces the recurrent infections. 
However, the virus remains latent in the sensory ganglia throughout the life. Acyclovir 
resistant strains have been identified. A study conducted by Centre for Disease Control and 
Prevention (CDC) states that about 5 % of the HSV II isolates obtained from HIV patients 
were found to be resistant for acyclovir.(61) 
HEPATITIS VIRUS: 
Viral hepatitis is caused by any one of the following agents namely Hepatitis A, B, 
C, D and E virus. The clinical presentation of infection by hepatitis viruses varies from 
asymptomatic infections to mild anicteric illness or it may present as severe prolonged 
jaundice or may end up in acute fulminant hepatitis, cirrhosis, malignancy. The mode of 
transmission for Hepatitis B and Hepatitis C infections is sexual, blood transfusion and 
through needle sticks injuries. Hence screening for HBV and HCV infections are 
mandatory during blood transfusion, during surgeries, during pregnancy and if the person 
is diagnosed with any of the sexually transmitted disease. About 10 to 20% of the total 
population has chronic carrier state of HBV infection.Both HBV and HCV have significant 
association with the causality of hepatocellular carcinoma that appears years after 
infection.  
HEPATITIS B VIRUS: 
HBV belongs to the family Hepadnaviridae. The virion is spherical in structure 
with an envelope enclosing a capsid and partly double stranded DNA genome. The surface 
proteins of the envelope are known as hepatitis B surface antigen (HBsAg). The capsid has 
icosahedral symmetry and it has dimers of core protein (HBcAg). In addition to above 
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antigens, a soluble virus protein is found in the blood of some infected individuals which is 
known as HBeAg. These main antigens induce corresponding antibodies i.e., Anti-HBsAg, 
Anti-HBeAg, Anti-HBcAg which are helpful for the diagnosis of infection and carrier 
state. HBV DNA polymerase is helpful in the early diagnosis. Cappel R et al., have found 
that the enzyme has been detected even in HbsAg negative cases. 
India accounts for 10 to 15% of the HBV carriers all over the world. The estimated 
prevalence of HBV carriers in India is around 40 million as estimated by various studies. 
NajmaJaved et al., found 10.46% of HbsAg positivity among women of reproductive age 
group in their study.(62) In  another  study,  it  was  estimated  that  the  prevalence  of  HbsAg  
positivity among the pregnant females is around 0.9 to 6.3%. (63)Vertical transmission of 
HBV to fetus causes low birth weight,  prematurity and chronic complications.  In women 
with acute hepatitis, the transmission rate is aroung 90%, whereas the chronic carrier state 
without immunoprophylaxis, the rate ranges from 10 to 20%. 
Laboratory diagnosis: 
 Even before the appearance of jaundice, the HBsAg can be detected in the serum 
and Anti-HBcAg is the first antibody to appear. Anti-HBsAg appears last in the course of 
infection and its presence indicates a state of complete recovery and immunity to 
reinfection. 
 The useful detection methods are ELISA for HBV antigens and antibodies and 
PCR  for  the  viral  DNA  analysis.  The  sensitivity  of  HEPALISA  used  in  India  is  around  
99%.(64) Rapid card test based on immunochromatography principle is also widely used but 
the sensitivity differs based on the manufacturer.  
Treatment: 
 IFN-alpha2b is given subcutaneously at a dose of 5 million units daily or 10 million 
units thrice weekly for 16 to 24 weeks. Oral lamivudine is given as 100mg/day for a period 
of 12 to 18 months and it is effective in reducing the HBV DNA levels. 
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HEPATITIS C VIRUS: 
HCV is a member of family Flaviviridae, which has a positive sense ssRNA. WHO 
estimates that 3% of the world’s population is infected with HCV.  Occult HBV infections 
(33%) are seen in patients with chronic HCV liver disease, where HBsAg cannot be 
detectable in serum because of its lower levels. The co-infections of Hepatitis infections 
with HIV are more common. There is no data about HCV infection rate in reproductive age 
group women, as it is not a part of routine screening method. But studies of HCV infection 
in  pregnant  women  are  available  which  shows  0.5%  (FI  Buseri  et  al.,)(65) and 5% 
(TehniyatIshaq et al.,)(66)  In a meta analysis, the pooled transmission rate of vertical 
transmission  of  HCV to  neonate  was  5.8%,  whereas  the  carriers  with  HIV co  infections,  
the rate is 10.8%. 
Laboratory diagnosis: 
 ELISA  and  immunoblot  tests  are  available  for  detecting  antibodies  to  core,  
envelope and NS3 and NS4 non structural proteins. ELISA has higher sensitivity when 
compared to the immunoblot rapid card tests. The limitations of immunoassays are 
inability to distinguish among acute, chronic or resolved infections. Nucleic acid based 
assays are helpful in detecting the presence of circulating HCV RNA and for genotyping. 
The viral  load assays are helpful in the monitoring of antiviral  therapy. The sensitivity of 
ELISA in detecting antibodies differs according to the manufacturer. In a comparative 
study,  the  HEPALISA  sensitivity  is  estimated  as  100%  and  the  specificity  is  98  to  
100%.(67) 
Treatment: 
 Interferon-Alpha2a or 2b given at the dose of 3 million units thrice weekly for 12 to 
24 months is effective. Ribavirin can also be given orally at a concentration of 1000-
1200mg daily for 6 to 12 months. 
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MISCELLANEOUS BACTERIA CAUSING RTI: 
 The microbial flora of the female genital tract is difficult to understand because of 
complexity of microbial colonization. Sometimes, even the endogenous organisms are the 
source of infections Eg: Bacterial vaginosis and many times the exogenous organisms like 
Escherichia coli, Klebsiellapneumoniae gets introduced in the host without causing any 
pathogenesis. Studies by Bartlett et al., have identified that the following organisms are the 
frequent colonizers of the female genital tract. These include Diphtheroids, Lactobacilli, 
Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus species, Escherichia 
coli, Proteus sp,Klebsiellasp, Pseudomonas sp. The ability of these organisms to become 
pathogenic is governed by the interactions between endogenous and exogenous 
environment. Some antimicrobial substances produced by the pathogenic organisms may 
cause destruction of endogenous flora and hence it may leads to infections. Although 
lactobacilli are the principal regulator of the flora, the commensal flora of other bacterial 
load alters the regulatory process and thus paves a threat for recurrent infections. 
 Many studies have estimated the bacterial causes of vaginitis and reported that 
Escherichia coli, Klebsiella sp., Proteus sp., Pseudomonas sp., Staphylococcus aureus and 
Streptococcus sp., are the most common bacterial agents affecting the lower genital tract. 
Samia S Khamees have estimated 21.8% Staphylococcus aureus, 14.2% Escherichia coli 
and 13.6% Klebsiella species infections in his study. Kouamouo et al have estimated 
34.9% of Escherichia coli, 23.8% of Enterobacter sp., 14.8% of Staphylococcus sp., 9% 
each of Citrobactersp and Streptococcus sp., 5.3% of Proteus sp., and 3.2% of Klebsiella 
sp.(68)The ascending infection from the lower genital tract causes pelvic inflammatory 
disease (PID) and it was substantiated by Spencer et al., in his study. 
Complications and sequel of RTI: 
 Many RTI are asymptomatic and its get unnoticed by most of the women. Gerbase 
et al., estimated that 70 to 75% of women infected with Chlamydia trachomatis had no 
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symptoms suggestive of RTI.  But the complications of such infections are dramatic.  40% 
of Chlamydial infections end up in Pelvic Inflammatory Disease (PID) which in turn leads 
to infertility, ectopic pregnancy and repeated fetal loss.  
 Syphilis can present with localized chancres, left if untreated can cause systemic 
manifestations like aneurysm, meningitis, stroke, gummas, visual defects, dementia. In 
pregnant  women,  the  transmission  to  child  leads  to  mid  trimester  abortion,  still  born  and  
baby born with birth defects. Studies estimated that 15 to 40% of syphilitic patients 
develop late complication, if left untreated. 
 The temporal association between bacterial vaginosis and complications is an 
ongoing debate.  It is related to increased risk of acquiring other sexually transmitted 
infections. It has a role in obstretic complications like pre term deliveries, miscarriage, 
chorioamnionitis, post abortion PID, post abortion endometritis. Several studies have 
emphazised that altered bacterial vaginal flora is responsible for the above complications 
(Johnson et al., 1985) and some studies have disapproved that (Alfonsi et al., 2004).(69,70) 
 Trichomonasvaginalis infections cause localized lesions, which increases the 
chance of acquiring HIV. In addition, it causes adnexitis, endometritis, pyosalpinx, 
infertility, low birth weight in pregnant females with TV. 
 Over all the reproductive tract infections have a direct impact on fertility, the risk 
of gynecological morbidities including PID, cervical erosions, cervical cancer and chance 
of transmission of other sexually transmitted infections. In addition to the physical burden, 
women with RTI suffer from psychological stress because of the symptoms and social 
stigma. Patel et al. concluded in his study that there is a significant link between vaginal 
discharge and mental health among the study group. Hence to overcome the physical, 
mental, psychosocial, economic burden of women due to reproductive tract infections, 
every nation should implement a protocol of screening, programs directed in the 
intervention of those diseases and also increase the research projects aimed at reducing the 
prevalence.  
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MATERIALS AND METHODS 

 Women with symptoms and signs suggestive of lower genital tract infections were 
selected and samples were collected from each individual. A total of 110 samples were 
collected over a period of one year which included vaginal swab, endocervical swab and 
blood. The samples were collected and processed as follows: 
Study design:  
Hospital based cross sectional study 
Study place:  
1. Department of Microbiology, Chengalpattu Medical College, Chengalpattu 
Tamil Nadu, India 
2. Department of Obstetrics & Gynecology, Chengalpattu Medical College 
and Hospital, Chengalpattu,Tamil Nadu, India 
Study period:  
One year (2014-2015) 
Study population: 
 Women of reproductive age group (18-45 years) 
Sample size:  
110 (It was proposed to include all the women over a period of one year who have 
fulfilled the inclusion criteria) 
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Ethical committee: 
 Ethical committee approval obtained from the institutional ethical committee, 
Chengalpattu Medical College. 
INCLUSION CRITERIA: 
x Age group 18 to 45 years 
x Women with history of 
1. Vaginal discharge 
2.  Low back ache 
3.  Abdominal pain 
4.  Infertility 
5.  Itching 
EXCLUSION CRITERIA: 
1. Unmarried women 
2. Pregnant women 
3. Women who have undergone hysterectomy 
4. Women on menstruation  
5. Women with diabetes, chronic illness 
6. Women who is on antimicrobial therapy 
7. Women who do not give consent 
Sample collection: 
 After getting informed consent, brief history was obtained by structured 
questionnaire related tosociodemographic profile, presenting complaints, past history, 
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history of contraceptive practices, obstretic history and menstrual history. Procedure for 
obtaining vaginal and endocervical swabs was explained to the patient before hand. 
Patients were asked to lie comfortably on the examination couch. In lithotomy position, 
under aseptic precautions, vaginal discharge was collected for wet mount, then three swabs 
from  posterior  vaginal  fornix  with  the  help  of  sterile  cotton  swabs  and  one  sample  from  
cervical os using Ayer`s spatula was collected.Vaginal discharge was immediately utilized 
for performing wet mount and Gram staining. The vaginal swabs were transported to the 
diagnostic microbiology laboratory as early as possible for culture. Sample from cervical 
os was used for Pap smear. 
A sterile swab was then introduced into the cervix to remove the cervical mucus 
secretions.The endocervical brushes was inserted one by one, 1 to 2 cm into the 
endocervical canal, rotated against the wall for 10 to 30 seconds, withdrawn without 
touching the vaginal surfaces and then placed in the appropriate transport medium. 
Oneendocervical brush was inoculated immediately in Modified Thayer Martin medium 
and incubated in candle extinction jar. Another endocervical brush was inoculated in a 
sterile aliquot tube containing 2ml of 99% ethanol for detecting Chlamydial nucleic acid 
by Real-time PCR. The aliquot tubes were carried in an ice-packed carrier and stored in 
deep freezer (-200C) immediately.  
 About 5ml of blood was collected from patient for serological examination. By 
centrifugation, serum was separated from blood sample and used for performing 
serological tests. 
1.  DIRECT MICROSCOPIC EXAMINATION: 
a)  WET MOUNT: 
 Few drops of discharge is kept on a clean glass slide and mixed with normal saline 
and overlaid with a coverslip and examined for the presence of pus cells, yeast cells, clue 
cells and for motile Trichomonasvaginalistrophozoites. 
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x Clue cells –  Dysmorphic epithelial cells with distinctive stipple appearance by 
being covered with bacteria 
x Trichomonasvaginalis – Pear shaped,  trophozoites with jerky movements 
b)  GRAM STAINING: 
Smear was made from vaginal discharge on a clean glass slide,  air  dried and heat 
fixed. Gram staining was done and observed for the presence of: 
x Epithelial cells 
x Pus cells 
x Clue cells, if seen Nugent scoring was done 
x Gram positive bacilli or cocci 
x Gram negative bacilli or cocci 
x Intracellular Gram negative diplococci 
x Yeast cells 
2.  MICROBIOLOGICAL CULTURE: 
a)  AEROBIC CULTURE: 
 The vaginal swab was inoculated on to a MacConkey agar plate and blood agar 
plate and incubated at 370C for 24 hours with 10% CO2. The colonies were read on the next 
day and the isolated organism was identified by Colony morphology, Gram staining, 
Catalase test, Oxidase test and other biochemical reactions. 
Antimicrobial susceptibility testing: 
 The isolated organism was subjected to antimicrobial susceptibility testing by disc 
diffusion method using modified Kirby-Bauer technique and interpreted as per CLSI 2014 
guidelines. Three to four morphologically similar colonies were suspended in peptone 
water  and  incubated  at  37°C  for  2  hours.  The  turbidity  of  the  test  suspension  was  
standardized to 0.5McFarland Units. The suspension was inoculated in Muller Hinton agar 
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plate with a sterile cotton wool swab by lawn culture method. After brief drying, the 
antibiotic discs were placed with sterile precautions, about 6 discs per 100mm plate. Then 
the plate was incubated at 37°C overnight and interpreted next day as per CLSI 2014, 
M100-S24, Volume 34, No.1.(71) 
PANEL OF DISCS USED FOR ANTIMICROBIAL SUSCEPTIBILITY TESTING 
OF ENTEROBACTERIACEAE 
Disc 
Sensitive 
(mm) 
Intermediate 
(mm) 
Resistant 
(mm) 
Gentamycin (10µg) 15 13-14 12 
Amikacin (30µg) 17 15-16 24 
Ciprofloxacin (5µg) 21 16-20 15 
Cefotaxime (30µg) 26 23-25 22 
Imipenam (10µg) 23 20-22 19 
 
PANEL OF DISCS USED FOR ANTIMICROBIAL SUSCEPTIBILITY TESTING 
OF STAPHYLOCOCCUS AUREUS 
 
Disc 
Sensitive 
(mm) 
Intermediate 
(mm) 
Resistant 
(mm) 
Penicillin (10 units) 29 - 28 
Amikacin (30µg) 17 15-16 14 
Cefoxitin (30µg) 22 - 21 
Trimethoprim - Sulfamethoxazole 
(1.25/23.75µg) 
16 11-15 10 
Ciprofloxacin (5µg) 21 16-20 15 
Erythromycin (15µg) 23 14-22 13 
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PANEL OF DISCS USED FOR ANTIMICROBIAL SUSCEPTIBILITY TESTING 
OF STREPTOCOCCUS SP., 
Disc Sensitive 
(mm) 
Intermediate 
(mm) 
Resistant 
(mm) 
Penicillin (10 units) 24 - - 
Trimethoprim - Sulfamethoxazole 
(1.25/23.75µg) 
19 16-18 15 
Ciprofloxacin (5µg) 21 16-20 15 
Erythromycin (15µg) 23 14-22 13 
 
b)  ANAEROBIC CULTURE: 
 Blood agar plates inoculated with one of the vaginal swab was incubated in 
McIntosh Fildes Jar along with anaerobic Gaspak for maintaining anaerobiasis and kept at 
incubator for 72 hours. After 72 hours, the blood agar plates were read for the presence of 
colonies. A nutrient agar plate with Pseudomonas aeruginosa was used as the anaerobic 
control. 
c)  FUNGAL CULTURE: 
 The other vaginal swab was inoculated in Sabourard`s dextrose agar and incubated 
at 370C.  The tube was regularly observed every day for growth upto 3 days and then on 
every alternate day till 7 days. Candida colonies were identified by colony morphology, 
Gram staining and further speciation was done. 
IDENTIFICATION OF CANDIDA SPECIES: 
i.  Germ tube test: 
 A Germ tube  is  defined  as  a  filamentous  extension  from a  yeast  cell  that  is  about  
half the width and three to four times the length of the mother cell. Germ tube test is 
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helpful in identification of Candida albicans and Candida dublinensis from other species 
of Candida. A light suspension of the test colonies was inoculated in 0.5ml of fresh human 
serum in a test tube. The tube was incubated at 370C for two hours. Exactly at two hours, 
one drop of the serum was placed in a clean glass side and prepared a mount with the help 
of cover slip and observed under low and high power for the production of Germ tubes. If 
there was 30% of the cell producing germ tubes, it was considered as positive. 
Approximately 5% of the Candida albicans may not produce germ tubes.(72) 
ii.  Dalmau plate culture: 
 The Dalmau plate culture was done on cornmeal agar and to observe for 
chlamydospore production in yeasts. It is one of the specific tests for the detection of 
Candida species. A heavy inoculum of the yeast colony was streaked across the medium by 
ploughing technique. A  coverslip was placed over it and the streak line should be beyond 
the cover slip. The plates were incubated at 250C  for  48  hours  in  a  closed,  moisturized  
chamber. After 48hours, the plates were examined under low power and high power for the 
presence and arrangement of Chlamydospores. 
CANDIDA SPECIES MORPHOLOGY 
Candida albicans Large, thick walled, terminal chlamydospores 
Candida tropicalis Blastospores singly or in small groups 
Candida kefyr Abundant pseudohyphae, elongated cells, log in 
stream appearance 
Candida krusei Elongated cells with tree like arrangement or crossed 
match stick appearance 
Candida parapsilosis Single blastospores or in small clusters with 
pseudohyphae 
Candida glabrata No pseudohyphae 
Candida dublinensis Chlamydospore formation 
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Sugar Fermentation tests: 
 The test suspension of organism was inoculated in the sugar fermentation media. It 
is a liquid media containing peptone(1%), sodium chloride(0.5%), filter sterilized sugars 
2% each of Glucose, Lactose, Sucrose and Maltose with indicator.  It was incubated at 
300C  for  48  hours.  When  the  colour  of  the  medium  changes  to  yellow,  it  indicates  
fermentation of sugars producing acid and gas in the Durham`s tube is checked. Production 
of acid and gas was taken as positive. 
Antifungal susceptibility testing: 
 The candida species isolated was subjected to antifungal susceptibility testing by 
disc diffusion method on Muller Hinton agar supplemented with 2% glucose and 0.5 ug/ml 
of methylene blue dye. Five similar looking colonies from 24 hour old culture of Candida 
sp.,  was  suspended  in  about  5  ml  of  normal  saline  and  it  was  matched  to  0.5  McFarland  
Standards. A sterile swab was dipped into the suspension and made a lawn culture in 
Muller Hinton agar. Commercial antifungal discs Fluconazole (10µg) and Voriconazole 
(1µg) were used and the zones of inhibition were measured after 24 hours of incubation at 
37° C according to CLSI M44-A, Volume 25, No.15.(73) 
PANEL OF DISCS USED FOR ANTIFUNGAL SENSITIVITY TESTING OF 
CANDIDA SP., 
Disc 
Sensitive 
(mm) 
Intermediate 
(mm) 
Resistant 
(mm) 
Fluconazole (10µg) 19 15-18 14 
Voriconazole (1µg) 17 14-16 13 
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CULTURE FOR NEISSERRIA GONORRHOEAE: 
The endocervical swab was inoculated aseptically at the side room in Modified 
Thayer Martin medium and incubated immediately in a candle extinction jar and carried 
over to the microbiological laboratory and placed in incubator (360C±1) maintaining 
humidity. Plates were examined after a period of 24 hours and if no growth was visible, it 
was again incubated upto 48 hours. 
 If the colonies appear on the selective medium, Gram stain, catalase test and 
oxidase test was performed. Gram negative diplococci, Catalase positive, Oxidase positive 
and sugar fermentation tests gives a presumptive identification of Neisseria gonorrhea. 
3. MOLECULAR METHOD FOR DETECTION OF CHLAMYDIA 
TRACHOMATIS: 
 The endocervicalcytobrush after collection was transported in aliquots containing 
99% ethanol as per the manufacturer`s instructions (HELINI® biomolecules) and stored in 
deep freezer (-200C) 
Protocol for Chlamydia trachomatis Real – time PCR assay: 
Materials:  
 HELINI PureFast®Bacterial DNA minispin purification kit, HELINI Chlamydia 
trachomatis Real-  time  PCR kit,  Instrument  used  was  Agilent  MX3000P Real  time  PCR 
machine 
Nucleic acid purification protocol: 
1.  200µl of lysis buffer was added to a nuclease free1.5ml centrifuge tube. 
2.  200µl of sample added then, after vortex mixed for 2 min. 
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3.  20µl of Proteinase K was added then, mixed immediately by inverting and 
incubating at 560C for 15min. 
4.  300µl of 100% ethanol was then added and mixed well by vortex for 30 
seconds. Spinning was done for few seconds to bring down drops to bottom of 
the tube. 
5. Then entire sample was pipette and transferred into the PureFast® spin column. 
Centrifuge at 12000rpm for 1 min. Discard the flow through and place the 
column back into the same collection tube. 
6.  500µl  of  wash  buffer-1  was  then  added  to  the  PureFast®  spin  column.  
Centrifuged at 12000rpm for 1 min and discarded the flow- through. The 
column back was placed into the same collection tube. 
7.  500µl of wash buffer-2 was added to the PureFast® spin column. Centrifuged 
at 12000rpm for 1 min and discarded the flow- through. The column back was 
placed into the same collection tube. 
8. Repeated Wash buffer-2 wash step once again. 
9. Centrifuged the empty spin column attached with collection tube at 12000rpm 
for an additional 1 min. This step is essential to avoid residual ethanol. 
Discarded the collection tube. 
10. Transferred the PureFast® spin column into a fresh 1.5ml micro centrifuge 
tube. 
11.  50µl  of  elution  buffer  added  to  the  center  of  PureFast®  spin  column  
membrane. Incubated for 2 minute at room temperature. 
12. Centrifuged at 12000rpm for 1 min and discarded the PureFast® spin column. 
Centrifuged the tube now which contains the eluted nucleic acid. It was used 
directly in PCR and aliquots stored at -800C for later analysis. 
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 REACTION MIX: 
Components Endogenous control Chlamydia trachomatis 
Probe PCR Master Mix 10 µl 10 µl 
Endogenous control primer probe 
mix 
5 µl -- 
Chlamydia trachomatis primer probe 
mix 
-- 5 µl 
Purified DNA sample 10 µl 10 µl 
Total reaction volume 25 µl 25 µl 
 
Negative control setup: 
 Use 5µl of nuclease free water instead of purified DNA sample as negative control. 
Positive control setup: 
  5µl of positive control template provided in the kit. 
 The PCR vials were centrifuged briefly before placing into thermal cycler. 
Amplification protocol: 
 Step Time Temperature 
Taq enzyme activattion 15 min 950C 
 
50 cycles 
Denaturation 20 sec 950C 
Annealing/Data collection 20 sec 560C 
Extension 20 sec 720C 
 
41 
Endogenous control = FAM channel (Human RNase P gene) 
Chlamydia trachomatis = FAM channel 
Real time interpretation was done by the amplification plots and by the ct value. 
4.  PAP SMEAR: 
 With the help of Ayre`s spatula, exfoliative cells from the squamocolumnar 
junction was evenly spread onto a glass slide. Then it was immediately fixed using 95% 
ethanol. Papanicaloau staining was done and the smear was examined for the presence of: 
x Inflammatory  cells 
x Shift in flora 
x Clue cells 
x Yeast cells 
x Trichomonasvaginalis 
x Microorganisms 
x Malignant cells 
5.  SEROLOGICAL ASSAYS: 
 5ml of blood was collected from each patient and the separated serum was used for 
performing serological tests. Samples were stored in deep freezer (-200C) for future 
reference. 
a)  RAPID PLASMA REAGIN TEST:  
 Rapid Plasma Reagin(RPR) test is an in vitro qualitative and semi quantitative test 
for diagnosis of syphilis. 
Principle: 
 The RPR reagent containing modified VDRL antigen(Cardiolipin antigen, lecithin 
and cholesterol) and microparticulate carbon particles, flocculate when mixed with serum 
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containing reagin. RPR is a screening test and the positive tests should be confirmed with 
specific confirmatory tests. 
Procedure: 
 RPR  kit  (Span  Diagnostics  Limited)  with  reagents  were  brought  to  room  
temperature. 
Qualitative test: 
The disposable cards are labeled with patient identification number 
1. Using disposable dropper, a drop of serum was placed in the card. Positive and 
negative controls were also tested with each set of test samples. 
2. The RPR reagent was gently shaked to resuspend the paricles. A drop of the 
reagent was added in all circles. 
3. The card was placed on the mechanical rotator and rotated for 8 minutes at 
100±2rpm 
4. Observe for floccules. 
Interpretation: 
Reactive specimen is indicated by macroscopically visible black clumps against clear 
background, in contrast non reactive specimen appear to have smooth uniform light gray 
colour. 
Semi quantitative test: 
 The positive samples were further tested for the titre by semiquantitative assay. 
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1. 50ul  of  0.9%  saline  solution  was  kept  in  the  2nd,  3rd,4th and  5th circles of the 
card by using a micropipette. 
2. 50ul of the sample was added in 1st circle and to the saline in the 2nd circle. 
3. 50ul of the diluted sample was aspirated from the 2nd circle and transferred to 
3rd circle. This was repeated upto 5th circle. 
4. 50ul from the 5th circle was aspirated and stored for further dilutions if needed. 
5. RPR antigen was added in each of the wells and then rotated well by placing in 
a mechanical rotator for 8 minutes at 100±2rpm. 
6. Observe for clumping in the circles. 
Interpretation: 
 The results are given as reactive with 1:2, 1:4, 1:8, 1:16 dilution with respect to the 
clumping observed in the circles.  The titre value of 1:8 is considered as significant titre. 
b)  TREPONEMA PALLIDUM HAEMAGGLUTINATION ASSAY: 
 IMMUTREP® TPHA (Omega diagnostics Ltd.,) is a specific and sensitive passive 
haemagglutination test for the detection of antibodies to Treponemapallidum in serum and 
CSF. It is the confirmation test for the diagnosis of syphilis. 
Principle: 
 The assay constituents consists of T.pallidum sensitized formolised tanned fowl 
erythrocytes; unsensitised formalized tanned fowl erythrocytes, diluents and control sera. 
When diluted positive samples are mixed with sensitized erythrocytes, antibody to the 
sensitizing antigen causes agglutination of the cells. The cells form a characteristic pattern 
of cells in the bottom of the microtitre plate. If there is no antibody, they form a compact 
button in the well.  
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Procedure: 
 All the sample and reagents were brought to room temperature before use. 
Qualitative test: 
1. For a single test 4 wells are needed in the microtitre plate 
2. The diluents was dispensed into the microtitration plate as follows: 25µl in 
rows 1,3 and 4; 100 µl in row 2. 
3. 25 µl of the sample was added in the well in row 1. It was mixed well and then 
25 µl was transferred from row 1 to row 2, then from row 2 to row 3 and then 
25 µl from row 3 was discarded. 
4. Then  25  µl  was  transferred  from  row  2  to  row  4  and  mixed  well.  25  µl  was  
discarded from row 4. 
5. 75 µl of the well mixed control cells were added to row 3. 
6. 75 µl of the well mixed test cells were added to row 4. 
7. Now the final dilutions in the row 3 and 4 are 1/80 
8. It was covered and left at room temperature for 60 minutes. 
9. After one hour, the wells were examined for agglutination patterns. 
Interpretation: 
x Agglutinated cells form an even layer at the bottom of the well and it is 
declared as reactive. 
x Non agglutinated  cells  form a  compact  button  in  the  centre  of  the  well  and  is  
declared as non reactive. 
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Quantitative procedure: 
1. The dilutions were prepared in the microtitre plate.  
2. Doubling dilutions were done starting from row 1. 
3. 75 µl of the well mixed control cells were added to row 1. 
4. 75 µl of the well mixed test cells were added to row 2 to 8. 
5. Final dilutions in row 1 and row 2 were 1/80. 
6. The plate was covered and left at room temperature for 60minutes. 
Interpretation: 
 The starting dilution was 1/80; hence the highest dilution which showed 
agglutination was taken as titre and the dilution was calculated accordingly. 
c) MICROWELL ELISA TEST FOR THE DETECTION OF HEPATITIS B 
SURFACE ANTIGEN: 
 HEPALISA is an invitro qualitative detection test for Hepatitis B surface antigen 
(HBsAg) in human serum or plasma. 
Principle: 
 HEPALISA is a solid phase Enzyme Linked ImmunosorbentAssay( ELISA) based 
on the direct sandwich principle. The microwells are coated with monoclonal antibodies 
with high reactivity for HBsAg. The samples are added in the wells followed by addition 
of enzyme conjugate. This leads to the formation of sandwich complex wherein HBsAg is 
sandwiched between the antibody and antibody HRPO conjugate. Unbound conjugate is 
washed off by wash buffer. The amount of bound peroxidase is proportional to the 
concentration of HBsAg in the sample. When substrate buffer and chromogen are added, a 
blue colour develops. The intensity of developed blue colour is proportional to the 
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concentration of HBsAg in the sample. To end the enzyme substrate reaction, stop solution 
is added and a yellow colour develops finally which is read at 450nm 
spectrophotometrically. 
Procedure: 
1. The test kit ( J.Mitra&Co.Pvt. Ltd.) and samples were brought to room 
temperature. 
2. The HEPALISA strips was fitted in the stripholder and labeling was done. 
3. 100µl of negative control was added in A1 and B1 wells. 
4. 100µl of positive control was added in C1 and D1 wells. 
5. The samples were added as 100 µl from E1 wells. 
6. Then 50µl of working enzyme conjugate was added to each well.  And the 
plate was covered and incubated at 370C±10C for 60 minutes. 
7. The wash buffer was diluted with distilled water to 1:25 dilution. 
8. After  one  hour,  the  plate  was  taken  from  incubator  and  washed  six  times  
with working wash buffer by ELISA washer. 
9. The wells  were  dried  and  100µl  of  working  substrate  was  added  in  all  the  
wells. 
10. The  plate  was  covered  with  aluminium  foil  and  incubated  at  room  
temperature (20 to 250C ) for 30 minutes in dark. 
11. 100µl of stop solution was then added to each well and mixed gently. 
12. The reaction was read at 450nm in ELISA reader. 
Calculation of results: 
x Positive control: PC value or its average should be more than 0.5, if not the test 
is considered as invalid. 
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x Negative control: NC value must be <0.150 . 
x Cut  off  value  :  Formula  =  NCഋ +  0.1  (NCഋ is  mean  absorbance  OD  of  the  
negative control) 
Interpretation of results: 
x Test specimens with absorbance value less than the cut off value were reported 
as non reactive. 
x Test specimens with absorbance value greater than or equal to the cut off value 
were reported as reactive. 
d) MICROWELL ELISA TEST FOR THE DETECTION OF ANTIBODIES TO 
HEPATITIS C VIRUS : 
 HCV Microlisa is an in-vitro qualitative third generation enzyme linked 
immunosorbent assay for the detection of antibodies against HCV(anti-HCV). 
Principle: 
 HCV Microlisa  utilizes  a  combination  of  antigen  with  the  sequence  of  both  HCV 
structural and non structural antigens like CORE, E1, E2, NS3, NS4 and NS5. Antibodies 
to HCV if  present in the sample bind to the immobilized HCV antigens on the microwell  
during the incubation period. The microwells are thoroughly washed with wash buffer and 
then enzyme conjugate added. The bound antigen-anti HCV-enzyme conjugate complex is 
formed. Now the substrate is added which leads to the development of blue colour 
indicating Ag-Ab reaction has occurred. Finally, stop solution is added to end the reaction 
and optical density is read photometrically. 
Procedure: 
 The kit with reagents(J.Mitra&Co.Pvt. Ltd.) were brought to room temperature. 
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1.  100ȝl Negative Control was added in well No.A-1. It is ready to use 
solution and hence no dilution was needed 
2.  100ȝl Positive Control was added in B-1, C-1 & D-1 wells.  
3.   100ȝl Sample Diluent was added in each well, starting from E-1 well 
followed by addition of 10ȝl sample. 
4.   The well plate was covered and incubated at 370C ± 30C for 30± 2 minutes. 
5.  Working wash solution and working conjugate solution were prepared as 
per the manufacturer`s instructions. 
6.   After  the  incubation  is  over,  the  wells  were  washed  6  times  with  working  
wash solution using ELISA washer. 
7.  Then 100 ȝl of Working Conjugate Solution was added in each well. 
8.  The well plate was covered and incubated at 370C ± 30C for 30± 2 minutes. 
9.  The working substrate solution was prepared in last 5 minutes of incubation 
and kept protected from light. 
10.  After the incubation is over, the wells were washed 6 times with working 
wash solution by ELISA washer. 
11.  Now, 100 ȝl working substrate solution was added in each well. 
12.   The well  plate was covered and incubated at  room temperature in dark for 
30 minutes. 
13.  100 ȝl of stop solution was then added. 
14.  With the help of ELISA READER, read absorbance at 450 nm . 
Calculation of results: 
x Positive control: PC value or its average should be more than 0.5, if not the 
test is considered as invalid. 
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x Negative control: NC value must be <0.150 . 
x Cut off value : Formula = PCഋ × 0.23   
Interpretation of results: 
x Test specimens with absorbance value less than the cut off value were reported 
as non reactive. 
x Test specimens with absorbance value greater than or equal to the cut off value 
were reported as reactive. 
e) ENZYME IMMUNOASSAY FOR DETERMINATION OF IgG 
ANTIBODIES TO HERPES SIMPLEX VIRUS TYPE 2: 
 DS-EIA-ANTI-HSV-2-G-FAST (DSI S.r.l. Italy) is for determination of IgG 
antibodies to Herpes Simplex Virus type 2 in human serum or plasma. 
Principle: 
 Microtiter wells as a solid phase are coated with HSV-2 antigens. During 
incubation with positive test sera, HSV type 2 specific antibodies bound to the 
immobilized antigens. The microwells are washed to remove the unbound serum proteins. 
Horseradish peroxidase conjugated anti-human IgG antibodies are dispensed in the washed 
wells. This results in  the formation of enzyme linked immune complexes. The microwells 
are washed to remove the unbound conjugate and then substrate is added. The colourless 
substrate is hydrolysed to a coloured end product in the presence of peroxidase. The 
intensity of the colour is  proportional to the amount of antibodies present in the patient`s 
serum. 
Procedure: 
1. The samples were diluted with the given sample diluent at 1:100 ratio. 
2. The controls were ready to use and hence they were not diluted. 
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3. 100µl of negative control, 100µl of positive control and 100µl of samples were 
added in the wells and incubated at room temperature for 15 minutes. 
4. The wells were washed with working wash buffer for 5 times with ELISA 
washer. 
5. 100µl of conjugate was pipetted in each well. 
6. The well plate was incubated at room temperature for 15 minutes. 
7. The wells were washed with working wash buffer for 5 times with ELISA 
washer. 
8. 100µl of TMB-substrate was added in each well. 
9. The well plate was incubated at room temperature for 5 minutes in dark. 
10. 100µl  of  stop  solution  was  added  into  each  well  and  the  results  were  read  by  
microplate reader at wavelength of 450nm. 
Calculation of results: 
 Cut – Off value = average OD of the negative control + 0.250 
 (0.250 = Co-efficient defined by the manufacturer) 
Interpretation of results: 
x The result of serum analysis is considered as positive, if OD/Cut-off > 1.1 
x The result of serum analysis is considered as negative, if OD/Cut-off<1.0 
STATISTICAL ANALYSIS 
 Data was formulated in terms of frequency distribution for different variables. As 
the data are categorical variable, Fischer test was employed as test of significance for 
testing associations. Multivariate logistic regression model for statistically significant 
predictors of lower genital tract infections were also tested. The data was analyzed using 
Epi-Info software (7.1.0.6 version; Center for disease control, USA) and Microsoft Excel 
2010. 
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RESULTS 
 
 Women with symptoms and signs suggestive of lower genital tract infections were 
selected and samples were collected from each individual. A total of 110 samples were 
collected over a period of one year which included vaginal swab, endocervical swab and 
blood. The samples were processed and the results are shown as follows. 
TABLE 1: AGEWISE DISTRIBUTION OF STUDY GROUP (n=110) 
Age (years) No. of patients Percentage (%) 
18-20 4 3.64 
21-25 48 43.64 
26-30 37 33.64 
31-35 11 10 
36-40 8 7.27 
41-45 2 1.81 
TOTAL 110 100 
 
 Age wise distributions of the subjects were analyzed. The range of age was 20 to 
43 years. The median age was 26. The majority (43.63%) of the study population were in 
the age group of 21 to 25 years, followed by the age group of 26 to 30 years (33.64%). 
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TABLE 2: TYPES OF RESIDENCE AMONG THE STUDY GROUP (n=110) 
Residence N % 
Rural 84 76.36 
Semiurban 26 23.64 
Urban 0 0 
Total 110 100 
 
 Among the study group, 84 (76.36%) belonged to rural area and 26 (23.64%) 
belonged to semi urban area. 
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TABLE 3: DISTRIBUTION OF OCCUPATION STATUS AMONG THE STUDY 
GROUP (n=110) 
Occupation 
( According to Kuppusamy scale) 
No of subjects % 
Unemployed 74 67.27 
Unskilled 29 26.36 
Semi skilled 3 2.73 
Skilled 1 0.91 
Clerical, shopowner, Farmer 1 0.91 
Semi professional 2 1.82 
Professional 0 0 
Total 110 100 
 
 74 out of 110 (67.27%) of the study subjects were unemployed, 29 out of 110 
(26.36%) were unskilled workers followed by 3 out of 110 (2.73%), who were semiskilled 
workers. 
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TABLE 4: PARITY WISE DISTRIBUTION OF STUDY GROUP (n=110) 
Parity No. of subjects (n) Percentage (%) 
Nulliparous 10 9.09 
Abortion/Still born 3 2.73 
One child (L1) 34 30.9 
Two child (L2) 54 49.1 
>Two child (>L2) 9 8.18 
Total 110 100 
 
 The majority of the study group (49.1%) had two children. 9.09% were nulliparous 
women and 2.73% had history of abortion/still born. 
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TABLE 5: SYMPTOM WISE DISTRIBUTION OF STUDY GROUP (n=110) 
 
Symptoms 
Present Absent Total 
No. of 
subjects 
 
% 
No. of 
subjects 
 
% 
No. of 
subjects 
 
% 
Discharge per 
vaginum 
82 74.55 28 25.45 110 100 
Lower abdomen pain 62 56.36 48 43.64 110 100 
Itching 26 23.64 84 76.36 110 100 
Burning micturition 19 17.27 91 82.73 110 100 
 
 Most of the study group population presented with more than one 
symptom.Discharge per vaginum (82, 74.55%) was the major presenting complaint, 
followed by abdomen pain (56.36%), itching (23.64%) and then burning micturition 
(17.21%). 
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TABLE 6:  DISTRIBUTION OF SYMPTOMS AMONG DIFFERENT AGE 
GROUPSIN THE STUDY POPULATION 
Symptoms 
Age  ӊ30yrs Age  > 30yrs Total 
No. % No. % No. % 
Discharge per vaginum 65 79.27 17 20.73 82 100 
Lower abdomen pain 50 80.65 12 19.35 62 100 
Itching 21 80.77 5 19.23 26 100 
Burning micturition 16 84.21 3 15.79 19 100 
 
 Most of the study group population presented with more than one symptom. 
Discharge per vaginum (65 out of 82, 17 out of 82) and lower abdomen pain (50 out of 62, 
12 out of 62) were the common symptoms in both study group of 30years and >30years 
respectively.  
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TABLE 7: DISTRIBUTION OF SYMPTOMS IN RELATION WITH PARITY 
 
Parity 
Discharge 
per vaginum 
(n=82) 
Lower abdomen pain 
(n=62) 
 
Itching 
(n=26) 
Burning 
Micturition 
(n=19) 
 No. % No. % No. % No. % 
Nulliparous 9 10.97 5 8.06 5 19.23 2 10.53 
Abortion/Still born 3 3.65 2 3.23 1 3.85 0 0 
One child 27 32.93 17 27.42 9 34.62 6 31.58 
Two child 35 42.68 33 53.23 9 34.62 9 47.37 
>2 child 8 9.75 5 8.06 2 7.69 2 10.53 
Total 82 100 62 100 26 100 19 100 
 
  Each subject presented with multiple complaints. Commonest symptom in relation 
with all types of parity in the study group population was discharge per vaginum (82) and 
lower abdomen pain (62). 
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TABLE 8: DISTRIBUTION OF CLINICAL SIGNS AMONG THE STUDY GROUP 
(n=110) 
 
Signs No of patients % 
Discharge per vaginum 44 40 
Redness 5 4.55 
Erosions 3 2.73 
Nodule 1 0.9 
Multiple signs 16 14.55 
No clinical  sign 41 37.27 
Total 110 100 
 
 Among the 110 subjects, 40% had Discharge per vaginum, 37.27% had no clinical 
sign, 14.55% had multiple signs like redness, erosions and nodule. All the study subjects 
who presented with symptoms of discharge per vaginum were not presented with the 
clinical sign as discharge per vaginum. 
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TABLE 9: DISTRIBUTION OF PAP SMEAR FINDINGS AMONG THE STUDY 
GROUP (n=110) 
 
Pap smear No. of subjects Percentage 
NILM 72 65.45 
Inflammation 17 15.45 
Yeast cells 15 13.64 
Clue cells 3 2.73 
TV 3 2.73 
Total 110 100 
 
 Among 110 subjects screened by pap smear, 61.82% had Negative for 
Intraepithelial Lesion or Malignancy (NILM), 15,45% had inflammation, 13.64% had 
yeast cells, 6.36% had clue cells and 2.73% had Trichomonasvaginalis. Pap smear finding 
correlated well with the etiological agents identified by microscopy and culture. 
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TABLE 10: LABORATORY DIAGNOSED CASES OF LOWER GENITAL TRACT 
INFECTIONS AMONG THE STUDY GROUP (n = 110) 
 
Laboratory diagnosis of 
lower genital tract infection 
No. of isolate % 
Positive 43 39.09 
Negative 67 60.91 
Total 110 100 
 
 Among 110 samples, laboratory diagnosis of lower genital tract infections was 
positive in 43 subjects (39.09%).  
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TABLE 11: DISTRIBUTION OF LABORATORY DIAGNOSED CASES WITH 
RESPECT TO TYPE OF INFECTIONS (n = 43) 
 
INFECTION No. of subjects % 
Single infection 36 83.72 
Mixed infection 7 16.28 
 
 Among 43 subjects who had laboratory findings for lower genital tract infections, 
36 (83.72%) presented with single infection and 7(16.28%) were presented with mixed 
infections. 
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TABLE 12: DISTRIBUTION OF STUDY GROUP WHO HAD LABORATORY 
FINDINGS FOR LOWER GENITAL TRACT INFECTIONS 
 
Type of 
infections Cases positive for laboratory diagnosis 
No. 
(n=43) % 
 
 
Single 
Infections 
 
Candida sp., 12 27.91 
Chlamydia trachomatis 5 11.63 
Trichomonasvaginalis (TV) 3 6.97 
Bacterial vaginosis (BV) 3 6.97 
Staphylococcus aureus 1 2.33 
Streptococcus sp., 1 2.33 
Escherichia coli 7 16.28 
Klebsiellapneumoniae 4 9.30 
 
Mixed 
Infections 
 
Candida+Chlamydia 1 2.33 
Candida+Staphylococcusaureus 1 2.33 
Candida+Escherichia coli 2 4.65 
Candida+Chlamydia+Escherichia coli 1 2.33 
Chlamydia+Citrobacterkoseri 1 2.33 
Chlamydia+Klebsiellapneumoniae 1 2.33 
 Total 43 100 
 
 Among the study group with single infections, Candida sp., was the most common 
agent (12, 27.91%) causing lower genital tract infections followed by Gram negative 
bacilli infections (11, 25.57%). Among the study group with mixed infections, Candida sp 
and C.trachomatis were the most common agents presented as mixed infections with other 
organisms.Laboratory diagnosis of bacterial vaginosis (6.97% positivity) was based on 
Nugent`s score. 
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TABLE 13: DISTRIBUTION OF LOWER GENITAL TRACT INFECTIOUS 
AGENTS IDENTIFIED BY VARIOUS MICROBIOLOGICAL METHODS (n = 48) 
 
Organisms No. of isolates Percentage 
Candida sp., 17 35.42 
Chlamydia trachomatis 9 18.75 
Trichomonasvaginalis 3 6.25 
Staphylococcus aureus 2 4.17 
Streptococcal sp., 1 2.08 
Citrobacterkoseri 1 2.08 
Klebsiellapneunomiae 5 10.42 
Escherichia coli 10 20.83 
Total  48 100 
 
 Candida sp.,(17, 35.42%) was the most common organism identified followed by 
Escherichia  coli  (10,  20.83%).  18.75%  of  the  samples  were  positive  for  C.trachomatis  
infection. 
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TABLE 14: DISTRIBUTION OF DIFFERENT SPECIES AMONG THE CANDIDA 
ISOLATES (n=17) 
 
Candida sp., No. of isolates Percentage 
Candida albicans 8 47.05 
Candida glabrata 3 17.65 
Candida tropicalis 3 17.65 
Candida kefyr 3 17.65 
Total 17 100 
 
 Among the isolated Candida sp., Non albicans species of Candida (52.95%) was 
the commonest organism followed by Candida albicans (47.05%). 
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TABLE 15: ANTIMICROBIAL SUSCEPTIBILITY PATTERN OF GRAM 
POSITIVE COCCI INFECTION 
 
Drugs 
Staphylococcus aureus 
(n=2) 
Streptococci sp., 
(n=1) 
S % S % 
Ampicillin 1 50 1 100 
Penicillin 1 50 1 100 
Amikacin 2 100 NA NA 
Cefoxitin 2 100 NA NA 
Cotrimaxozole 1 50 1 100 
Ciprofloxacin 2 100 1 100 
Erythromycin 1 50 1 100 
 
 Staphylococcus aureus isolates had 100% sensitivity to amikacin, ciprofloxacin and 
cefoxitin, whereas 50% of the isolates were sensitive to ampicillin, penicillin, 
erythromycin and cotrimaxozole.  
 Streptococcus sp., had 100% sensitivity to ampicillin, penicillin, ciprofloxacin, 
cotrimaxozole and erythromycin. 
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TABLE 16: ANTIMICROBIAL SUSCEPTIBILITY PATTERN OF GRAM 
NEGATIVE BACILLI INFECTION 
 
 
Drugs 
Escherichia coli 
(n=10) 
Kleb. pneumoniae 
(n=5) 
Citrobacterkoseri 
(n=1) 
S % S % S % 
Gentamycin 7 70 3 60 1 100 
Amikacin 10 100 5 100 1 100 
Ciprofloxacin 7 70 3 60 1 100 
Cefotaxime 7 70 5 100 1 100 
CefotaximeClavulanic 
acid 
10 100 5 100 1 100 
Imipenam 10 100 5 100 1 100 
 
 All Gram negative isolates were 100% sensitive to amikacin, cefotaximeclavulanic 
acid and imipenam. 
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TABLE 17: ANTIFUNGAL SUSCEPTIBILITY PATTERN OF ISOLATED 
CANDIDA SP., 
Antifungal 
drug 
C.albicans 
(n=8) 
C.glabrata 
(n=3) 
C.tropicalis 
(n=3) 
C.kefyr 
(n=3) 
No. % No. % No. % No. % 
Fluconazole 
(25ug) 
 
8 
 
100 
 
3 
 
100 
 
3 
 
100 
 
3 
 
100 
Voriconazole 
(1ug) 
 
8 
 
100 
 
3 
 
100 
 
3 
 
100 
 
3 
 
100 
 
 All the Candida isolates have 100% sensitivity to fluconazole (25ug) and 
voriconazole (1ug). 
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TABLE 18: DISTRIBUTION OF LABORATORY DIAGNOSED CASES IN 
RELATION TO AGE GROUP 
 
 
Age 
Candida 
sp., 
Chlamydia 
trachomatis 
Trichomonas 
vaginalis 
Bacterial 
vaginosis 
Aerobic 
bacteria 
Poly 
microbial 
No % No % No % No % No. % No % 
 30 years 9 75 5 100 2 66.67 3 100 7 53.85 7 100 
> 30 years 3 25 0 0 1 33.33 0 0 6 46.15 0 0 
Total  12 100 5 100 3 100 3 100 13 100 7 100 
 
 Candida sp., was the commonest agent (75%) causing lower genital tract infections 
in study group  30 years and aerobic bacterial agents were the commonest agent among > 
30 years age group study population. Whereas, Poly microbial infections were seen only in 
age group 30 years. Over all, lower genital tract infections were common among women 
 30 years with significant p value (0.0037) 
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TABLE 19: DISTRIBUTION OF LABORATORY DIAGNOSED CASES IN 
RELATION WITH PARITY 
 
PARITY 
Candida 
Species 
Chlamydia 
Trachomatis 
Trichomonas 
vaginalis 
Bacterial 
Vaginosis 
Aerobic 
bacteria 
Poly 
microbial 
No. % No. % No. % No. % No. % No. % 
Nulliparous 1 8.33 0 0 1 33.33 1 33.33 0 0 2 28.56 
Abortion 0 0 0 0 0 0 1 33.33 1 7.69 1 14.29 
One child 
(L1) 
5 41.67 2 40 0 0 1 33.33 4 30.77 3 42.86 
Two child 
(L2) 
4 33.33 3 60 2 66.67 0 0 5 38.46 1 14.29 
>2 child 
(>L2) 
2 16.67 0 0 0 0 0 0 3 23.08 0 0 
Total 12 100 5 100 3 100 3 100 13 100 7 100 
 
 Candida sp., was the most common agent affecting all the parity groups with 
majority of study group belonging to L1 (41.67%). Aerobic bacteria was commonly 
identified among all groups of parous women (L1, L2,>L2).Over all, lower genital tract 
infections were common among the women with multi parity with significant p value 
(0.0797) 
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TABLE 20: SIGNIFICANCE OF SYMPTOMS AND SIGNS IN LOWER GENITAL 
TRACT INFECTIONS 
 
 
Variables Positive lab findings % 
Negative 
lab 
findings 
% Total % 
 SY
M
PT
O
M
S 
Discharge 37 86.05 45 67.16 82 74.55 
Abdomen pain 23 53.49 39 58.21 62 56.36 
Itching 18 41.86 8 11.94 26 23.64 
Burning 
Micturition 10 23.26 9 13.43 19 17.27 
 SI
G
N
S 
No sign 6 13.95 35 52.24 41 37.27 
Discharge PV 35 79.55 9 20.45 44 40 
Redness 5 100.00 0 0.00 5 4.55 
Erosions 3 100.00 0 0.00 3 5.45 
Nodule 0 0.00 1 100 1 1.82 
Multiple sign 13 81.25 3 18.75 16 14.55 
 
 The symptom of Discharge per Vaginum and Itching acts a significant predictor for 
lower genital tract infections with p value of 0.0423 and 0.0005 respectively. All the 
clinical signs are statistically significant for the development of lower genital tract 
infections. 
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TABLE 21: SIGNIFICANCE OF CONTRACEPTION IN LOWER GENITAL 
TRACT INFECTIONS 
 
Contracept
ion 
Positive laboratory 
diagnosis (n=43) 
Negative laboratory 
diagnosis  (n=67) 
Total 
( n = 110) 
No. % No. % No. % 
Nil 12 27.91 19 28.36 31 28.18 
Barrier 1 2.33 3 4.48 4 3.64 
IUCD 9 20.93 3 4.48 12 10.91 
Tubectomy 21 48.84 42 62.69 63 57.27 
Total 43 100 67 100 110 100 
 
 Among the subjects with lower genital tract infectious agents identified, 9 out of 12 
(20.93%) were IUCD users with significant p value (0.0107). 
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TABLE 22: DISTRIBUTION OF CO INFECTIONS AMONG THE STUDY GROUP 
 
Co infection 
Positive laboratory 
diagnosis (n=43) 
Negative laboratory 
diagnosis  (n=67) 
Total 
(n=110) 
No. % No. % No. % 
HBV 0 0 2 2.99 2 1.82 
HCV 0 0 0 0 0 0 
HSV 2 17 39.53 11 16.42 28 25.45 
HIV 0 0 0 0 0 0 
Syphilis 0 0 1 1.49 1 0.91 
 
 HSV – 2 was the commonest co infection among both the laboratory confirmed and 
not confirmed cases, 39.53% and 16.42% respectively. P value was significant (0.0127) for 
association between HSV-2 co infections in lower genital tract infections. Note: HIV 
screening was done for high risk groups as a screening modality in ICTC centre and the 
results were taken with informed consent obtained from the subjects. 
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TABLE 23: MULTIVARIATE LOGISTIC REGRESSION MODEL FOR 
STATISTICALLY SIGNIFICANT PREDICTOR OF LOWER GENITAL TRACT 
INFECTIONS 
 
Independent Variables 
RTI Positivity 
Odds Ratio 95% Confidence Interval P value 
Age < 30 years 0.6482 0.2486 to 1.6901 0.3753 
Parity > 2 1.3900 0.4336 to 4.4555 0.5796 
Abortion 5.2703 1.0117 to 27.4546 0.0484 
Contraception 1.0226 0.4361 to 2.3978 0.9591 
Semi Urban Residence 1.4654 0.6022 to 3.5662 0.3997 
Unemployment 0.6818 0.2778 to 1.6736 0.4032 
Spouse Occupation- Unskilled 0.4259 0.1631 to 1.1126 0.0815 
Presence of Co Infection 3.3287 1.3673 to 8.1033 0.0081 
 
 On multivariate analysis of independent variables, the risk factors for developing 
genital tract infections were observed.Abortion has 5 times higher risk (5.2703 odds) and 
associated co infections positive people has 3 times higher risk (3.3287 odds) of 
developing lower genital tract infections 
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DISCUSSION 



 This study was conducted at the Department of Microbiology, Chengalpattu 
MedicalCollege in association with Department of Obstetrics and Gynecology, 
Chengalpattu Medical College and Hospital. A total of 110 subject who presented with the 
symptoms and signs of lower genital tract infections during the one year study period and 
who satisfied the inclusion criteria were included in the study. 
 Our country is in a state of epidemiological and demographical transition where 
morbidity and mortality rates may differ from previous demographic studies. In the last 
few years, community based studies on lower genital tract infections have been carried out 
in various parts of our country. Yet, South Indian studies are not widely available.  
 The socio demographic profile has a direct impact on the occurrence of lower 
genital tract infections and it was analyzed in our study. Age is one of the pivotal 
vulnerable factors in genital tract infections. The range of age group in our study 
population was from 18 to 45 years (Table 1) with the majority of age group between 21-
25years (43.64%) followed by 26-30 years (33.64%). The predominant age distribution of 
20-29 years is in accordance with other community based studies conducted by Shalini S et 
al.,2011 (74.3%) and Savita Sharma et al., 2009 (63.6%).(74,75) Half of all the genital tract 
infections occur in this age group of 15 to 24 years and in some nations, 60% of all new 
infections occurred among these age group individuals (Brabinet al.,1995).(76)This 
increased trend in relation to age is because they belonged to more sexually active age 
when compared to other age groups.  
 As our study was conducted in a semi urban area, 76.36% of the study population 
belonged to rural community and 23.64% belonged to semi urban community (Table 2). In 
a review article by GayatriDesiet al., the prevalence of symptoms of genital tract infections 
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was 39.3% and 33.6% in rural and urban India respectively.(77)Krishna ray et al., reported 
74.8% in  rural  India  and  68.1% in  urban  India.(78)Various studies have also depicted that 
there was no major difference in the prevalence of lower genital tract infections in rural 
and urban areas.  
 An increasingly observed factor which determines the morbidity is the occupation 
status of the individual and spouse. 67.27% were homemakers and the remaining study 
subjects (32.73%) were employed (Table 3). Majority of them were belonging to unskilled 
occupation (26.36%). Similar findings were observed in a study conducted by Prasad et al., 
in Tamil Nadu in which 55% were performing household chores and 77.5% in another 
study by Neerajaet al., 2009.(33,79)  The occupation status has a prime role in determining 
the occurrence of genital tract infections based on migration, duration of contact with 
partners, emotional bonding with partners, skill, knowledge and awareness about genital 
tract infections. 
 Age, residence and occupation are the hinges for determining the awareness of 
women about gynecological morbidities, decision making capacities and treatment seeking 
behavior in a rural society with stigma and discrepancies towards genital tract infections.  
 Another strong association is attributed to parity and genital tract infections. In our 
study, about 49.1% who presented with symptoms of lower genital tract infections 
belonged to L2 group (Table 4). Our study result correlated with study conducted by 
Sangeetha S Balamuruganet al.,  who  have  reported  that  the  prevalence  of  RTI  was  33%  
among women with more than one children and it gets increased on increasing parity.(80)   
The chance of getting a reproductive tract infections were 1.5times more among women 
who had more number of pregnancies than with fewer pregnancies as evidenced by study 
conducted by Prasad et al.,(33)  There is also a strong link between the nature of deliveries 
and history of abortion, unsafe practices during delivery and factor for developing genital 
tract infection with significant p value of 0.0797 (Table 19) 
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 A large number of studies have correlated well with contraceptive usage and genital 
tract infections. 9 out of 12 IUCD users (20.93% among the laboratory diagnosed cases) in 
our study (Table 20) were proven for laboratory diagnosed genital tract infection with 
significant p value (0.0107).  Wasserheitet al., have estimated that women who were using 
IUCD have seven times increased risk of Pelvic inflammatory disease (PID) than with no 
contraceptive usage.(81)    Similarly a South Indian study by Bhatia et al., showed there was 
2.5 times increased risk for IUCD users in developing PID.(82) This has correlated well with 
our study results. The reasons for IUCD and genital tract infections are mainly attributed to 
the IUCD tail which facilitates the ascent of infectious organisms and also there is a 
change in the cervicovaginal flora which could favor for bacterial vaginosis. Out of 63 
subjects who underwent permanent sterilization, 21(48.84%) presented with laboratory 
findings suggestive of lower genital tract infections. Even though it sounds to be clinically 
significant, statistical significance could not be obtained. This is in accordance with study 
conducted by Prasad et al., (23%) (33) The reason for increased number of infections in PS 
cases is due to lack of usage of barrier methods and increased sexual exposure. 
 Among the symptoms of lower genital tract infections identified in our study 
(Table 5, 6, 7), Discharge per vaginum (74.55%) was the major presenting complaint 
followed by lower abdomen pain (56.36%), Itching (23.64%) and burning micturition 
(17.21%).  Anjanavermaet al.,  have  reported  that  the  prevalence  of  symptoms  of  lower  
genital  tract  infections  were  around  41.8% in  rural  Delhi,  in  which  41.8% discharge  PV,  
10% lower abdomen pain, 3% burning micturition and 1% dyspareunia .(83)   National 
Family Health Survey -3 concluded that prevalence of these symptoms among Indian 
women ranged between 11 to 18% in nationwide studies. In some other studies by Rani et 
al., and Prasad et al., the range varied from 40 to 57%. (33,84) M.L.S Prabhaet al., found that 
the sensitivity and specificity for diagnosing a genital tract infection by vaginal discharge 
was 58.95% and 55.13% respectively.(85)   For  lower  abdomen  pain,  the  sensitivity  was  
very low (14.49%), but specificity of 76.63%. This correlated well with our findings that in 
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laboratory diagnosed subjects, discharge and itching were found to be significant with p 
values 0.0423 and 0.0005 respectively (Table 21).  Since our study was a hospital based 
study with lesser sample size and it included only symptomatic women, the percentages of 
individual symptoms seems to be in an increased way, when compared with community 
based studies.. As discharge per vaginum occurs also as a physiological phenomenon and 
the perception of symptoms differs from individual to individual, the reliability of patient`s 
history is lacking in genital tract infections. There is a necessity to do laboratory based 
diagnosis to overcome this drawback and to estimate the exact prevalence data. 
 The distribution of clinical signs (Table 8, 21) in our study has shown that out of 82 
subjects who had discharge per vaginum as the primary complaint, only 44 presented with 
white discharge per vaginum on speculum examination. Among 44 subjects with vaginal 
discharge, only 30 (68.18%) was diagnosed with lower genital tract infections by 
laboratory methods. This warrants that symptoms based treatment has a drawback and it 
should be given only after proper speculum examination and laboratory evaluation of each 
individual to avoid unnecessary medication and improper estimation of prevalence data. 
Out of 41 subjects who presented with no characteristic clinical sign, 6 (13.95%) were 
diagnosed with lower genital tract infection by laboratory method. This signifies that the 
subjects may have taken a course of empirical treatment or the infection per se presented 
without any clinical signs. The correlation of these findings could not be obtained as there 
is lack of statistical data for individual clinical signs. On analyzing individual clinical 
signs, statistical significance was obtained in our study.Sangeetha S Balamuruganet al., 
2012 have estimated 72.4% positivity for clinical signs in symptomatic women with 
RTI.(80)   Hence it is advisory to screen all the reproductive age group women with feasible 
laboratory method at regular intervals to prevent sequelae.   
 The cervical region is both a sentinel target for genital tract infection and 
carcinoma. Women presenting with symptoms and signs suggestive of RTI should be 
evaluated by Pap to distinguish between malignancy and infection, as cervical cancer is the 
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second  most  common  cause  of  cancer  among  women  in  our  country.  Moreover,  chronic  
pelvic infections leads to inflammatory changes that adds up the risk for developing into 
malignancy. In our study, the findings of the routine cytological screening of women with 
leucorrhea were taken and the scoring was done according to Bethesda system. None of 
them had malignant changes, whereas 15.45% had inflammatory changes, 13.64% had 
yeast cells, 2.73% had clue cells and 2.73% had Trichomonasvaginalis(Table 9). In a study 
conducted by Smith et al., 16.2% of Bacterial vaginosisand 31% candidiasis were 
identified by Pap smear.(86)  The proportion is lesser in our study as there is lesser sample 
size when compared to other studies. 88.23% of Candidiasis, 100% of bacterial vaginosis, 
100% of Trichomonasvaginalis cases diagnosed by microbiological methods has been 
identified readily by Pap smear in our study. Data from Lions –FSH project, Palakad 
figured out that 41.5% inflammation, 6.5% Candidiasis, 6.2% Trichomonasvaginalis was 
identified  by  Pap  smear  in  their  control  suburban  population.  The  above  finding  implies  
that Pap smear can also be used as a screening modality in resource poor settingsfor 
identifying genital tract infections.   
 Out of 110 vaginal swabs which were subjected to wet mount microscopy, Gram 
staining, aerobic and anaerobic culture, fungal culture and the endocervical swabs which 
were subjected to culture for N.gonorrhea and  Real  time  PCR assay  for  the  detection  of  
C.trachomatis, 43(39.09%) of the cases were positive for any one of the agents commonly 
causing lower genital tract infections (Table 10). This correlates well with a study 
conducted in rural area of Vellore district in Tamil Nadu by Prasad et al., which showed 
53% of women reported gynecological symptoms and 38% had laboratory findings for 
genital tract infections. (33)   M.L.S Prabhaet al., have estimated the prevalence of 33.1% in 
their study population.(85) Kosambiyaet al., conducted a similar study at Surat with 
comparison of rural and urban prevalence showing 53% and 69% respectively.(86)  The 
higher prevalence in urban areas is due to knowledge and awareness about genital tract 
infections and easy accessibility to tertiary care centres. 
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 The findings of laboratory diagnosed cases were evaluated and it was estimated that 
in our study about 83.72% had single infection and 16.28% had mixed infections(Table 
11). Among the individuals with single infections, the distributions were 27.91% Candida 
sp., 11.63% Chlamydia trachomatis, 6.97% Trichomonasvaginalis, 6.97% Bacterial 
vaginosis, 2.33% Staphylococcus aureus, 2.33% Streptococcus sp., 16.28% Escherichia 
coli and 9.30% Klebsiellapneumoniae infections(Table 12). The mixed infections had 
various combinations with Candida sp., and C.trachomatis.Prasad et al., figured out that 
10% of vaginal candidiasis, 18.2% of bacterial vaginosis, 1.8% Chlamydia trachomatis 
and 12.9% Trichomonasvaginalis as laboratory diagnosed infection rate.(33) M.L.S.Prabha 
et al., estimated 14.3% bacterial vaginosis, 6% Candidiasis, 3% Chlamydia trachomatis, 
1% Trichomonasvaginalis and 8.8% of secondary bacterial infections.(85)   The differences 
in the figures in our study is due to lesser sample size,  hospital  based study while all  the 
comparative study groups are community based studies. 
 Bacterial vaginosis, as such is a clinical term diagnosed by Amsel criteria. The 
sensitivity and specificity of Amsel criteria is 37% and 99% respectively (Beverely E shaet 
al.,). (87) We have estimated 6.97% of BV cases by the gold standard laboratory diagnostic 
method i.e.,Nugent scoring (Table 12). There is a low level of estimation in our study 
when compared to other studies (RohitChawla et al., 32.86% and TamonudModak et al., 
24%). (88.89) Since only laboratory method was employed, correlation between Amsel 
criteria method and Nugent scoring method could not be obtained in our study. The 
consequences  of  BV include  abortion,  still  birth,  preterm deliveries  and  co  infections  are  
also more common. 100% of bacterial vaginosis cases affected the women with age group 
30 years. This correlated well with SaradaTiyaggura et al., who have estimated that the 
majority  of  bacterial  vaginosis  affects  30  years  women  (53.1%).   Hence  in  addition  to  
screening of high risk groups, all child bearing age group and pregnant women should be 
screened for BV to avoid such complications. 
81 
 The agents causing the lower genital tract infections were analyzed individually 
and it was estimated that 35.42% were Candida sp (Table 13). Among them, 47.05% 
Candida albicans, 17.65% Candida glabrata, 17.65% Candida tropicalis, 17.65%C. kefyr 
(Table 14). There is slightly increased prevalence when compared to other studies. Jindal 
et al., estimated 23.4% culture positive for Candida sp., with 74.4% of Candida 
albicans,11% Candida glabrata, 6% Candida tropicalis, 3.6% Candida krusei and 2.43% 
Candida parapsilosis and Candida guillermondi each.(90) Anisahmad et al., estimated 
20.47% prevalence of Candida sp., with Candida glabrata 36.7%, Candida parapsilosis 
10.2%, Candida tropicalis 2.8%, Candida kefyr 1.8% and Candida krusei 1.4%. (91) 75% of 
Candida isolates affected 30years which gets correlated with a study conducted by 
SujithD.Rathod et al., 2012. (92) Vulvovaginal candidiasis (VVC), as such is not a sexually 
transmitted disease but the majority of women presenting with leucorrhea is diagnosed 
with VVC.  Non albicans species of Candida is in increased prevalence for the recent 
years. The risk of recurrent infections is more common if the infection is not properly 
treated. Also, there is increased prevalence of resistant strains among Candida sp., due to 
inadvertent usage of antifungal treatment (Zahra salehi et al.,).(93)  It is advised to perform 
antifungal susceptibility testing for all candida isolates to give appropriate treatment and to 
avoid the raising antifungal resistance strains.  In our study, according to CLSI disk 
diffusion zone interpretation method, all the isolates (100%) were sensitive for 
Fluconazole (25ug) and Voriconazole (1ug). Quindoset al. study showed that the 
sensitivity of Candida species to fluconazole and ketoconazole was 90.2% and 91.4% 
respectively.(94)  Many more studies have estimated the resistance pattern and concluded 
that it is advisable to do antifungal susceptibility testing in order to battle against the 
emerging antifungal drug resistance. 
 Chlamydia trachomatis (18.75%) was the proportion obtained from our study 
(Table 13). The prevalence rate of C.trachomatis by PCR is 7.04% (Dwibediet al.,) and 
23% (Daman Salujaet al.,)(95,96)   The increased proportion of Chlamydia trachomatis in 
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our study is attributed to the molecular diagnostic technique employed i.e., Real-time PCR 
detection method which has higher sensitivity when compared to other methods. Jaton K et 
al., have identified that the sensitivity and specificity of Real time PCR is 95.7% and 100% 
respectively.(97)  As Chlamydia trachomatis presents as asymptomatic infection, untreated 
genital tract infection can lead to ramifications for the childbearing age group women. It is 
a  must  to  screen  for  all  the  child  bearing  age  group  women  for  C.trachomatis infection 
with cost effective methods. The available diagnostic techniques like ELISA are not a 
reliable indicator and at least in resource rich areas, molecular methods are advisable to 
estimate the exact prevalence of C.trachomatis infection.Similar to findings observed by 
Ugbomaet al., and Mawaket al., Chlamydia trachomatis (100%) affected the age group 
30 years in our study (Table 18).This finding is evidenced by Corbeto et al.,2010 in his 
study.(98,99) The reasons for the significance of this age group and C.trachomatis infections 
is due to early coitarche, inconsistent use of barrier methods and multiple sexual  partners. 
There is a need to educate the young sexually active females to avoid risky sexual practices 
and to undergo periodic screening for C.trachomatis. Health programmes should be 
implemented to screen the clinically silent C.trachomatis infections at an early age (<25 
years) to safeguard the reproductive health of women. 
 6.25% of lower genital infections were contributed by Trichomonasvaginalis in our 
study (Table 13). This is in accordance with 8.5% estimated by Madhivannanet al.,(44)  As 
TV is a treatable infection, the consequences like preterm deliveries, transmissibility to sex 
partner, increased exposure for other sexually transmitted infections can be prevented 
when appropriate etiological diagnosis is obtained. In developing countries, the screening 
modalities are mainly aimed at high risk groups leaving behind the study population 
belonging to community, where the exact prevalence data is submerging. In our study, 
only  wet  mount  method  was  used  as  the  modality  of  diagnosis  of  TV.  The  sensitivity  of  
wet mount method is 55% (Sood s et al.,)(100) ShivkumarShetkarhave estimated that the 
prevalence of TV by wet mount and broth culture method was 0.5% and 3% respectively. 
Accordingly, there is an underestimation of the TV cases in our study and if broth culture 
method has been employed, the actual data could be obtained. However, our estimation 
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reflects the methodology employed in a developing country like India, where wet mount is 
the universal method of screening (NACO guidelines). 
 Among the aerobic bacterial infections, 6.25% (4.66% as single infection, 1.59% as 
mixed infection) caused by Gram positive cocci and 33.33% (25.58% as single infection,  
7.75% as mixed infection) by Gram negative bacilli (Table 13).  The difference between 
colonization and infections was established by the presence of active symptoms, presence 
of pus cells in wet mount and Gram staining, presence of inflammation in Pap smear 
findings and remission of symptoms following treatment. Staphylococcus aureus isolates 
showed 100% sensitivity to amikacin, ciprofloxacin and cefoxitin, whereas only 50% 
isolates showed sensitivity to ampicillin, penicillin, erythromycin and cotrimaxozole. 
Streptococcus sp., had 100% sensitivity to ampicillin, penicillin, ciprofloxacin, 
cotrimaxozole and erythromycin (Table 15) The gram negative isolates were 100% 
sensitive to amikacin, cefotaximeclavulanic acid and imipenam (Table 16). The above 
results were substantiated by Samia S Kamees and J.Kouamouoet al., in their studies.(68)  
 In  our  study,  the  age  group  30  years  were  more  prone  for  poly  microbial  
infections (16.28%) with significant p value of 0.0037 (Table18). This is in accordance 
with a study conducted by Richard Omorogieet al., 2010 where the prevalence of mixed 
infections was 25.16%.(101)  The findings of parity analysis in our study showed that mixed 
infections were equally distributed in almost all the types of parity groups.  
 On analyzing the subjects with laboratory diagnosed lower genital tract infections, 
HSV 2 was the predominant co infectious agent (39.53%) with significant p value 
(0.0127). The positivity of HBV (2.99%), Syphilis (1.49%) and HSV 2 (19.42%) were 
noted in laboratory undiagnosed cases of our study group (Table 22). This differs from 
other research studies like Devinderet al., (82.9% HSV 2 infection) and Madhivannanet 
al.,(11.3% HSV 2 infection). (57,44)  This  variation  in  the  data  is  supported  by  a  global  
review narrated by Smith and Robinson who suggested that HSV-2 prevalence depends 
upon residence, population subgroup, age and sex. 
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 In our study group, there was nil clinical sign (i.e., Chancre) suggestive of primary 
syphilis.  Serological screening for syphilis revealed 1.49% positivity in the study 
population as detected by RPR which was further confirmed by TPHA. This finding is 
corroborative with 1.5% of syphilis cases identified by Prasad et al.,(33)  
 Women of child bearing age have a risk of transmission of HBV to their offspring 
and hence it is a must to screen all the women for HBV infection and carrier state. 2.99% 
of  our  study  group  was  positive  for  HBV.  This  is  an  underestimate  when  compared  with  
NajmaJaved (14.07%) and Yu Zhang (9.51%), which is mainly due to lesser sample 
size.(62)  
 A number of studies have been conducted to demonstrate the prevalence of HBV, 
HSV, HIV and syphilis among reproductive age group women. Many studies have 
postulated a strong association between HSV-2 positivity and HIV/Syphilis infections. 
However, no such association was made in our study due to different set of population 
involved in various studies. The vulnerability of women to acquire HSV, HBV, HIV, HCV 
and syphilis is due to lack of knowledge about the infection rates, insufficient access to 
prevention, inability to adopt safer sex due to male dominance and lack of easy availability 
of female condoms. Hence targeted interventions should be aimed at prevention strategies 
through information and health education.  
 The significance of individual risk factors for developing lower genital tract 
infections was finally compiled and evaluated in our study by multivariate logistic 
regression analysis (Table 23). It showed abortion has 5 times higher risk (5.2703 odds) 
and associated co infections positive people  has 3 times higher risk (3.3287 odds) of 
developing lower genital tract infections. 
  
85 
SUMMARY 
  
 This study conducted at the Department of Microbiology, Chengalpattu Medical 
College, Chengalpattu aimed at analyzing the microbiological profile of lower genital tract 
infections revealed the following findings. 
x Out of 110 subjects, 43 subjects (39.09%) were identified with laboratory 
findings for lower genital tract infections. 
x Lower genital tract infections were common among women with age  30 years 
and parity belonging to L2 group. 
x Women who were IUCD users (20.93%) were more affected with lower genital 
tract infections. 
x Discharge per vaginum (86.05%) and Itching (41.86%) were the significant 
symptoms seen in the 43 subjects who had laboratory findings for lower genital 
tract infections. 
x All the clinical signs were found to be statistically significant for diagnosing 
lower genital tract infections. 
x Out of 43 laboratory diagnosed cases, 83.72% presented with single infection 
and 16.28% with mixed infections. 
x 6.97% cases of Bacterial Vaginosis were estimated in our study. 
x On analysis of individual agents causing lower genital tract infections, 35.42% 
Candida sp., 20.42% Escherichia coli, 10.42% Klebsiellapneumoniae, 6.25% 
Trichomonasvaginalis, 4.17% Staphyloccocusaureus, 2.08% each of 
Streptococcus sp., and Citrobacterkoseri was identified in our study. 
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x 18.75% of Chlamydia trachomatis was identified as etiological agent in genital 
tract infections by Real time PCR assay. 
x Out of 17 Candida sp., 47.05% was Candida albicans and 17.65% each of 
Candida glabrata, Candida tropicalis, Candidakefyr. 
x Staphylococcus aureus isolates had 100% sensitivity to amikacin, ciprofloxacin 
and cefoxitin (MSSA). 
x Streptococcus species had 100% sensitivity to ampicillin, penicillin, 
ciprofloxacin, cotrimaxozole and erythromycin. 
x All Gram negative isolates were 100% sensitive to amikacin and imipenam. 
x All the Candida isolates had 100% sensitivity to fluconazole and voriconazole. 
x Pap smear findings revealed 13.64% yeast cells, 2.73% each of Bacterial 
Vaginosis and Trichomonasvaginalis which correlated well with microscopy 
and culture. 
x On screening for co infections, out of 110 subjects, 25.45% HSV-2, 1.82% 
HBV, 0.91% Syphilis positivity was observed in our study. Among them, 
39.53% HSV-2 positivity were laboratory diagnosed cases for lower genital 
tract infections.  
x Abortion has 5 times higher risk (5.2703 odds) and associated co infections 
positive people has 3 times higher risk (3.3287 odds) of developing lower 
genital tract infections. 
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CONCLUSION 

 This study conducted at the Department of Microbiology, Chengalpattu Medical 
College, Chengalpattu, aimed at analyzing the microbiological profile of lower genital tract 
infections had revealed that accurate diagnosis of lower genital tract infections can be 
established  by  laboratory  based  methods.   The  findings  of  our  study  have  thrown  some  
light on the dark shades of stigmatized society, where the estimation of exact prevalence of 
genital tract infections is cumbersome.  
 A  complex  interplay  of  factors  like  sexual  promiscuity,  unprotected  sexual  
behavior, stigma towards genital tract symptoms and non availability of screening 
modalities at all health centres contributes to increased occurrence of genital tract 
infections in our country. Community based studies should be conducted at regular 
intervals to estimate the socio-demographic transition status of genital tract infections all 
over  the  country.  This  focus  helps  in  timely  intervention  by  formulating  new  policy  and  
programmes to improve the reproductive health of women. 
 As Chlamydia trachomatis is  the most common cause of treatable RTI worldwide 
and it presents mostly as asymptomatic infection, screening is mandatory for all the child 
bearing age group women to avoid consequences like PID and infertility. Hence it is 
recommended to take a prudent action on implementing a nationwide screening 
programme for Chlamydia trachomatis. 
 To conclude, laboratory diagnosis for women with symptoms and signs is 
suggested when compared to syndromic approach. Screening for sexually transmitted 
infections by serological methods are mandatory in women with symptoms and signs of 
genital tract infections. In addition, Pap smear can be used as a reliable indicator for 
screening genital tract infections in resource poor areas. 
88 
BIBLIOGRAPHY 


1. World Health Organisation. (2005). A guide to essential practice, Sexually 
Transmitted and other reproductive tract infections. WHO. 
2. Centre for Disease Control and Prevention. (June 2003). Reproductive Health 
Epidemiology Series Module 3. Atlanta. USA: CDC.  
3. National AIDS Control Organisation. (phase III). National STI/RTI control and 
prevention program. India: NACO. 
4. Malhotra, M., Sood, S., Mukherjee, A., Muralidhar, S., &Bala, M. (2013). Genital 
Chlamydia trachomatis: An update. The Indian Journal of Medical Research, 
138(3), 303–316.  
5. Meenakshi Malhotra, M. B. (2008). Prevalence of Chlamydia trachomatis and its 
association with other sexually transmitted infections in a tertiary care hospital, 
North India. Indian journal of Sexually transmitted diseases , 82-85.  
6. T. Hussain, ,. K. (2008). HIV, HBV, HCV, and syphilis co-infections among 
patients attending the STD clinics of district hospitals in Northern India. 
International journal of infectious diseases , 358-363. 
7. Ray, K., Bala, M., Bhattacharya, M., Muralidhar, S., Kumari, M., &Salhan, S. 
(2008). Prevalence of RTI/STI agents and HIV infection in symptomatic and 
asymptomatic women attending peripheral health set-ups in Delhi, India. 
Epidemiology and Infection, 136(10), 1432–1440.  
8. Nagarkar Aarti, M. P. (2015). A systematic review on the prevalence and 
utilization of health care services for reproductive tract infections/sexually 
transmitted infections: Evidence from India. Indian journal of Sexually Transmitted 
Diseases and AIDS , 18-25. 
9. World Health Organisation. (2014). Fact Sheet on STI/RTI. WHO 
apps.who.int/iris/bitstream/10665/112323/1/WHO_RHR_14.10_eng.pdf 
10. Alejandra Vásquez1, T. J. (2002). Vaginal Lactobacillus Flora of Healthy Swedish 
Women . Journal of Clinical Microbiology , 2746-2749 
89 
11. Martino, J. L., &Vermund, S. H. (2002). Vaginal Douching: Evidence for Risks or 
Benefits to Women’s Health. Epidemiologic Reviews, 24(2), 109–124. 
12. E.R.  Boskey1,  R.  C.  (2001).  Origins  of  vaginal  acidity:  high  d/l  lactate  ratio  is  
consistent with bacteria being the primary source . oxford journals , 1801- 1813. 
13. Desa, G. S. (n.d.). Incidence of reproductive tract infections and sexually 
transmitted diseases in india: levels anddifferentials. The Journal of Family 
Welfare, pp. 48 - 60. 
14. Centre for Disease control and prevention, c. f. (2007). Trends in Reportable 
Sexually Transmitted Diseases in the United States, 2007. United States: CDC. 
15. Khairun  Nessa1,  S.-A.  W.  (2004).  Epidemiology  and  Etiology  of  Sexually  
Transmitted Infection among Hotel-Based Sex Workers in Dhaka, Bangladesh. 
Journal of clinical microbiology , 618-621. 
16. Gottlieb SL1, L. N. (2014). Toward global prevention of sexually transmitted 
infections (STIs): the need for STI vaccines. Vaccine , 1527-35. 
17. National AIDS control Organisation. (2013-2014). Annual Report . India: NACO. 
18. NagarkarAarti, MhaskarPallavi ( 2015) A systematic review on the prevalence and 
utilization of health care services for reproductive tract infections/sexually 
transmitted infections: Evidence from India, Indian journal of Sexually Transmitted 
Diseases and AIDS, Page: 18-25 
19. National AIDS control Organisation. (2015). Narrative country progress report of 
India: Global AIDS response progress reporting . India: NACO. 
20. Hatcher(2004), Contraceptive practices Page 192, Ardent media 
21. AsimKurjak, Frank A. Chervenak (2006), Textbook of Perinatal Medicine, Second 
edition, Page 1688 
22. Joyee AG, Thyagarajan SP, Sowmya B, Venkatesan C, Ganapathy M (2003), Need 
for specific and routine strategy for the diagnosis of genital chlamydial infection 
among patients with sexually transmitted diseases in India. Indian J Med Res 
118:152-7 
90 
23. Malhotra M, Bala M, Muralidhar S, Khunger N, Puri (2008). Prevalence of 
Chlamydia trachomatis and its association with other sexually transmitted 
infections in a tertiary care center in North India. Indian J Sex Transm Dis;29:82-5. 
24. Centre for Disease Control and Prevention, Aetna Policy,Chlamydia trachomatis -  
Screening and diagnosis , No.0433 
25. P.A.Mardh, J.Paavonen, M.Puolakkainen, (2012), Chlamydia, Springer science & 
Business media , page 75 
26. Chernesky, M. A. (2005). The laboratory diagnosis of Chlamydia trachomatis 
infections. The Canadian Journal of Infectious Diseases & Medical Microbiology, 
16(1), 39–44. 
27. MeenakshimalhotraSeemaSood, Anjan Mukherjee, 
SumathiMuralidhar&ManjuBala (2013), Genital Chlamydia trachomatis - an 
update, Ind J Med Res pp306-316 
28. Abida  Malik,  S.  Jain,  S.  Hakim,  I.  Shukla&  M.  Rizvi  (2006),  Chlamydia  
trachomatis infection and female infertility , Ind J of Med Res123, p770-775 
29. David Greenwood, Richard C B Slack, Michael R. Barer,  Will  L Irving,  Medical 
Microbiology: A Guide to Microbial Infections: Pathogenesis Page 387 
30. Chlamydiaceae infections: Advances in research and treatment: 2011 edition 
31. Achkar, J. M., & Fries, B. C. (2010). Candida Infections of the Genitourinary 
Tract. Clinical Microbiology Reviews, 23(2), 253–273.  
32. Bang RA, Baitule M, Sarmukaddam S, Bang AT, Choudhary Y, Tale O (1989) 
High prevalence of gynaecological diseases in rural Indian women. Lancet. 
;1(8629):85–88 
33. Prasad JH, Valentine G, Lalitha MK, Jayapaul MN, Abraham S, NandiniShetty N, 
et al. Vellore: Christian Medical College; (2003). Prevalence of reproductive tract 
infections among adolescents in a rural community in Tamil Nadu. Population and 
Health info share, document information organization-International Centre for 
Research on women; pp. 1–7. 
34. Madhivanan, P., Bartman, M. T., Pasutti, L., Krupp, K., Arun, A., Reingold, A. L., 
&Klausner, J. D. (2009). Prevalence of Trichomonasvaginalis infection among 
91 
young reproductive age women in India: implications for treatment and prevention. 
Sexual Health, 6(4), 339–344.  
35. Mirrett, S., Lauer, B.A., Miller, G.A., Reller, L.B., 1982. Comparison of acridine 
orange, methylene blue, and Gram stains for blood cultures. J. Clin. Microbiol. 15, 
562–566. 
36.  Preethi, V., Mandal, J., Halder, A., Parija, S.C., 2011. Trichomoniasis: An update. 
Trop. Parasitol. 1, 73–75. doi:10.4103/2229-5070.86934 
37. Jahan, N., Ahmad, S., Khan, H., Rabbani, T., Khatoon, R., 2015. Comparison of 
four diagnostic techniques for detection of Trichomonasvaginalis infection in 
females attending tertiary care hospital of North India. Indian J. Pathol. Microbiol. 
58, 36. 
38.  Huppert, J.S., Batteiger, B.E., Braslins, P., Feldman, J.A., Hobbs, M.M., Sankey, 
H.Z.,  Sena,  A.C.,  Wendel,  K.A.,  2005.  Use  of  an  Immunochromatographic  Assay  
for Rapid Detection of Trichomonasvaginalis in Vaginal Specimens. J. Clin. 
Microbiol. 43, 684–687. 
39.  Lisi, P.J., Dondero, R.S., Kwiatkoski, D., Spence, M.R., Rein, M.F., Alderete, J.F., 
1988. Monoclonal-antibody-based enzyme-linked immunosorbent assay for 
Trichomonasvaginalis. J. Clin. Microbiol. 26, 1684–1686. 
40.  Barbara A. Majeroni, Bacterial Vaginosis: An Update - American Family 
Physician. 1998. 
41.  PS, R., 2004. Diagnosis of bacterial vaginosis in a rural setup: Comparison of 
clinical algorithm, smear scoring and culture by semiquantitative technique. Indian 
J. Med. Microbiol. 22, 47. 
42.  Padubidri, V.G., Daftary, S.N., 2014. Shaw’s Textbook of Gynecology.Elsevier 
Health Sciences. Page 384 
43.  Sweet,  R.L.,  Gibbs,  R.S.,  2012.  Infectious  Diseases  of  the  Female  Genital  
Tract.Lippincott Williams & Wilkins. 
44. Madhivannan, Purnima., 2009, Simple and Inexpensive point of care tests improve 
diagnosis of vaginal infections in resource constrained situations.,Tropical 
medicine and International health, pp 32-35 
92 
45.  Bhalla, P., Chawla, R., Garg, S., Singh, M.M., Raina, U., Bhalla, R., Sodhanit, P., 
2007. Prevalence of bacterial vaginosis among women in Delhi, India. Indian J. 
Med. Res. 125, 167–172. 
46.  Sachdeva, S., 2006. Clue cell. Indian J. Dermatol. Venereol. Leprol. 72, 392. 
47.  Amsel, R., Totten, P.A., Spiegel, C.A., Chen, K.C., Eschenbach, D., Holmes, 
K.K., 1983. Nonspecific vaginitis. Diagnostic criteria and microbial and 
epidemiologic associations. Am. J. Med. 74, 14–22. 
48.  Nugent, R.P., Krohn, M.A., Hillier, S.L., 1991. Reliability of diagnosing bacterial 
vaginosis is improved by a standardized method of gram stain interpretation. J. 
Clin.Microbiol. 29, 297–301. 
49.  Whiley, D.M., Tapsall, J.W., Sloots, T.P., 2006. Nucleic Acid Amplification 
Testing for Neisseria gonorrhoeae. J. Mol. Diagn. JMD 8, 3–15.  
50.  Prasad, J.H., Abraham, S., Kurz, K.M., George, V., Lalitha, M.K., John, R., 
Jayapaul, M.N.R., Shetty, N., Joseph, A., 2005. Reproductive tract infections 
among young married women in Tamil Nadu, India. Int. Fam. Plan. Perspect. 31, 
73–82.  
51. Sood, S., Manjubala, Kapil, A., Sharma, V., Verma, R., 2009. Diagnostic approach 
to gonorrhoea: Limitations. Indian J. Sex. Transm. Dis. AIDS 30. 
52. J. D. Schmale, J. E. Martin, and G. Domescik, “Observations on the culture 
diagnosis of gonorrhea in women,” JAMA, vol. 210, no. 2, pp. 312–314, Oct. 1969. 
53. J.  D. Klausner,  “The NAAT is out of the bag,” Clin. Infect. Dis. Off. Publ. Infect. 
Dis. Soc. Am., vol. 38, no. 6, pp. 820–821, Mar. 2004. 
54. A. Jain, V. Mendiratta, and R. Chander, “Current status of acquired syphilis: A 
hospital-based 5-year study,” Indian J. Sex. Transm. Dis., vol. 33, no. 1, pp. 32–34, 
2012. 
55. A. G. D. of Health, “Syphilis Laboratory Case Definition (LCD).” Australian 
Government Department of Health, 2012. 
56. N. K. Naidu, Z. S. Bharucha, V. Sonawane, and I. Ahmed, “Comparative study of 
Treponemal and non-Treponemal test for screening of blood donated at a blood 
center,” Asian J. Transfus. Sci., vol. 6, no. 1, pp. 32–35, 2012. 
93 
57. Devinder et al., “Indian Journal of Dermato Venereology, Jan_05. 
58. S. K. Sukhbir and S. K. Sukhbir, “Neonatal Herpes Simplex Infection, Neonatal 
Herpes Simplex Infection,” Int. Sch. Res. Not. Int. Sch. Res. Not., vol. 2013, 2013, 
p. e473053, Aug. 2012. 
59. J. LeGoff, H. Péré, and L. Bélec, “Diagnosis of genital herpes simplex virus 
infection in the clinical laboratory,” Virol. J., vol. 11, p. 83, May 2014. 
60. M. J. Slomka, L. Emery, P. E. Munday, M. Moulsdale, and D. W. Brown, “A 
comparison of PCR with virus isolation and direct antigen detection for diagnosis 
and typing of genital herpes,” J. Med. Virol., vol. 55, no. 2, pp. 177–183, Jun. 1998. 
61. CDC, “Genital Herpes - STD information from CDC,” 2015.[Online]. Available: 
http://www.cdc.gov/std/herpes/.  
62. N. Javed and S. Naz, “Prevalence Of Hepatitis B Infection In Married Women Of 
Child Bearing Age In District Islamabad,” Gomal J. Med. Sci., vol. 11, no. 2, Jan. 
2014. 
63. M. Dwivedi,  S.  P.  Misra,  V. Misra,  A. Pandey, S.  Pant,  R. Singh, and M. Verma, 
“Seroprevalence of hepatitis B infection during pregnancy and risk of perinatal 
transmission,” Indian J. Gastroenterol., vol. 30, no. 2, pp. 66–71, Mar. 2011. 
64. World Health Organization and Department of Essential Health Technologies, 
Hepatitis B surface antigen assays: operational characteristics (phase I). Report 2. 
Report 2. Geneva: World Health Organization, 2004. 
65. F. Buseri, E. Seiyaboh, and Z. Jeremiah, “Surveying Infections among Pregnant 
Women in the Niger Delta, Nigeria,” J. Glob. Infect. Dis., vol. 2, no. 3, pp. 203–
211, 2010. 
66. TehniaytIshaq, “Frequency and risk factors of hepatitis C among pregnant women.” 
Gomal Journal of Mediacl Sciences, 2011. 
67. S.  Maity,  S.  Nandi,  S.  Biswas,  S.  K.  Sadhukhan,  and  M.  K.  Saha,  “Performance  
and diagnostic usefulness of commercially available enzyme linked immunosorbent 
assay and rapid kits for detection of HIV, HBV and HCV in India,” Virol. J., vol. 9, 
p. 290, Nov. 2012. 
94 
68. J. Kouamouo, R. F. Kwetchep, D. Yangoue, and others, “Female genital tract 
infections and engines of antibiotic resistance in fastgrowing populations of 
Bangangte, West-Cameroon,” Int J Pharm, vol. 4, no. 3, pp. 181–186, 2013. 
69. S. R. Johnson, C. R. Petzold, and R. P. Galask, “Qualitative and quantitative 
changes of the vaginal microbial flora during the menstrual cycle,” Am. J. 
Reprod.Immunol. Microbiol. AJRIM, vol. 9, no. 1, pp. 1–5, Sep. 1985. 
70. D. Rakel and R. E. Rakel,  Textbook of Family Medicine: Expert Consult: Online. 
Elsevier Health Sciences, 2015. 
71. Performance standards for antimicrobial susceptibility testing. (m100-s24). [Place 
of publication not identified]: Clinical And Laboratory, 2014. 
72. E. W. Koneman, Color atlas and textbook of diagnostic microbiology. J.B. 
Lippincott, 1992. 
73. CLSI M44, Method of antifungal disk diffusion susceptibility testing of yeasts - 
Approved guideline CLSI M44-A, Volume 25, No.15. . 
74. Shalini, S., Murthy, N.S., Shalini, C.N., Rajanna, M.S., Geethamani, V., 2011. 
Study of Reproductive tract infections among women attending Urban Health 
Centres in Banglore City. Indian J PrevSoc Med 42, 267–72. 
75.  Sharma, S., Gupta, B., 2009. The prevalence of reproductive tract infections and 
sexually transmitted diseases among married women in the reproductive age group 
in a rural area.Indian J. Community Med. Off. Publ. Indian Assoc. Prev. Soc. Med. 
34, 62–64.  
76.  Brabin, L., Roberts, S.A., Fairbrother, E., Mandal, D., Higgins, S.P., Chandiok, S., 
Wood, P.,  Barnard,  G.,  Kitchener,  H.C.,  2005. Factors affecting vaginal pH levels 
among female adolescents attending genitourinary medicine clinics. Sex. Transm. 
Infect. 81, 483–487. 
77.  Desai, G.S., Patel, R.M., 2011. Incidence of Reproductive tract infections and 
Sexually transmitted Diseases in India: Levels and Differentials. J. Fam. Welf. 57, 
48–60. 
78.  Ray, K., Muralidhar, S., Bala, M., Kumari, M., Salhan, S., Gupta, S.M., 
Bhattacharya, M., 2009. Comparative study of syndromic and etiological diagnosis 
95 
of reproductive tract infections/sexually transmitted infections in women in Delhi. 
Int. J. Infect. Dis. 13. 
79.  Jindal, N., Aggarwal, A., Gill, P., Sabharwal, B., Sheevani, B.B., 2009. 
Community-based Study of Reproductive Tract Infections, Including Sexually 
Transmitted Infections, Among the Rural Population of Punjab, India. Indian J. 
Community Med. Off.Publ. Indian Assoc. Prev. Soc. Med. 34, 359–361. 
80. Balamurugan, S.S., Bendigeri, N., 2012. Community-Based Study of Reproductive 
Tract Infections Among Women of the Reproductive Age Group in the Urban 
Health  Training  Centre  Area  in  Hubli,  Karnataka.Indian  J.  Community  Med.  Off.  
Publ. Indian Assoc. Prev. Soc. Med. 37, 34–38.  
81.  Washington, A.E., Cates, W., Wasserheit, J.N., 1991. Preventing pelvic 
inflammatory disease. JAMA 266, 2574–2580. 
82.  Bhatia, J.C., Cleland, J., 1995. Self-reported symptoms of gynecological morbidity 
and their treatment in south India. Stud. Fam. Plann. 26, 203–216. 
83. Verma, A., Kumar Meena, J., Banerjee, B., Verma, A., Kumar Meena, J., Banerjee, 
B.,  2015.  A  Comparative  Study  of  Prevalence  of  RTI/STI  Symptoms  and  
Treatment Seeking Behaviour among the Married Women in Urban and Rural 
Areas of Delhi Int. J. Reprod. Med. Int. J. Reprod. Med. 2015, 2015. 
84. Prasad JH, George V, Lalitha MK, Jayapaul MN, Abraham S, Shetty N, et al. 
Prevalence of Reproductive Tract Infection among Adolescents in a Rural 
Community in Tamil Nadu. Paper presented at the Workshop on Reproductive 
Health in India: New Evidence and Issues, Pune, February 28-March 1. 2000 
85.  Prabha, M.L.S., Sasikala, G., Bala, S., 2012. Comparison of syndromic diagnosis 
of reproductive tract infections with laboratory diagnosis among rural married 
women in Medak district, Andhra Pradesh. Indian J. Sex. Transm. Dis. 33,112–115.  
86.  Smith, L., 1998. Bacterial vaginosis. Nurs. Times 94, 50–51. 
87.  Sha, B.E., Chen, H.Y., Wang, Q.J., Zariffard, M.R., Cohen, M.H., Spear, G.T., 
2005.  Utility  of  Amsel  Criteria,  Nugent  Score,  and  Quantitative  PCR  for  
Gardnerellavaginalis, Mycoplasma hominis, and Lactobacillus spp. for Diagnosis 
96 
of Bacterial Vaginosis in Human Immunodeficiency Virus-Infected Women. J. 
Clin. Microbiol. 43, 4607–4612.  
88.  Chawla, R., Bhalla, P., Chadha, S., Grover, S., Garg, S., 2013. Comparison of 
Hay’s Criteria with Nugent’s Scoring System for Diagnosis of Bacterial 
Vaginosis.BioMed Res. Int. 2013. 
89.  Modak, T., Arora, P., Agnes, C., Ray, R., Goswami, S., Ghosh, P., Das, N.K., 
2010. Diagnosis of bacterial vaginosis in cases of abnormal vaginal discharge: 
comparison of clinical and microbiological criteria. J. Infect. Dev. Ctries. 5, 353–
360. 
90.  Jindal, N., Gill, P., Aggarwal, A., 2007. An epidemiological study of vulvovaginal 
candidiasis in women of childbearing age. Indian J. Med. Microbiol. 25, 175–176. 
91.  Ahmad, A., Khan, A.U., 2009. Prevalence of Candida species and potential risk 
factors for vulvovaginal candidiasis in Aligarh, India. Eur. J. Obstet. Gynecol. 
Reprod. Biol. 144, 68–71.  
92.  Rathod, S.D., Klausner, J.D., Krupp, K., Reingold, A.L., Madhivanan, P., Rathod, 
S.D., Klausner, J.D., Krupp, K., Reingold, A.L., Madhivanan, P., 2012. 
Epidemiologic Features of Vulvovaginal Candidiasis among Reproductive-Age 
Women in India, Epidemiologic Features of Vulvovaginal Candidiasis among 
Reproductive-Age Women in India. Infect. Dis. Obstet. Gynecol. Infect. Dis. 
Obstet. Gynecol. 2012, 2012. 
93.  Salehei, Z., Seifi, Z., Mahmoudabadi, A.Z., 2012. Sensitivity of Vaginal Isolates of 
Candida to Eight Antifungal Drugs Isolated From Ahvaz, Iran.Jundishapur J. 
Microbiol. 5, 574–577. 
94.  Quindós, G., Abarca, L., Carrillo-Muñoz, A.J., Arévalo, M.P., Bornay, F.J., 
Casals, J.B., Hernández-Molina, J.M., Iglesias, I., Linares, M.J., Martín-Mazuelos, 
E., PereiroFerreirós, M., Rezusta, A., Rubio, M.C., Salesa, R., San Millán, R., 
Torres-Rodríguez, J.M., 1999. Multicenter survey of in vitro antifungal resistance 
in yeasts of medical importance isolated from Spanish patients. Rev. Iberoam. 
Micol. 16, 97–100. 
97 
95. Dwibedi, B., Pramanik, J., Sahu, P., Kar, S., Moharana, T., 2009. Prevalence of 
genital Chlamydia infection in females attending an Obstetrics and Gynecology out 
patient department in Orissa. Indian J. Dermatol. Venereol. Leprol. 75, 614. 
96. Patel, A.L., Sachdev, D., Nagpal, P., Chaudhry, U., Sonkar, S.C., Mendiratta, S.L., 
Saluja, D., 2010. Prevalence of Chlamydia infection among women visiting a 
gynaecology outpatient department: evaluation of an in-house PCR assay for 
detection of Chlamydia trachomatis. Ann. Clin. Microbiol. Antimicrob. 9, 24. 
97.  Jaton,  K.,  Bille,  J.,  Greub,  G.,  2006.  A novel  real-time  PCR to  detect  Chlamydia  
trachomatis in first-void urine or genital swabs. J. Med. Microbiol. 55, 1667–1674.  
98.  Arinze, A.U.H., Onyebuchi, N.V., Isreal, J., 2014. Genital chlamydia trachomatis 
infection among female undergraduate students of University of Port Harcourt, 
Nigeria. Niger. Med. J. J. Niger. Med. Assoc. 55, 9–13.  
99.  Mawak, J.D., Dashe, N., Agabi, Y.A., Panshak, B.W., 2011. Prevalence of Genital 
Chlamydia Trachomatis Infection among Gynaecologic Clinic Attendees in Jos, 
Nigeria.Shiraz E-Med. J. 12, 100–106. 
100.  Sood, S., Kapil, A., 2008. An update on Trichomonasvaginalis. Indian J. Sex. 
Transm. Dis. AIDS 29, 7. 
101. Omoregie, R., Egbe, C.A., Igbarumah, I.O., Ogefere, H., Okorie, E., 2010. 
Prevalence and etiologic agents of female reproductive tract infection among in-
patients and out-patients of a tertiary hospital in Benin city, Nigeria. North Am. J. 
Med. Sci. 2, 473–477.  
 
 ABBREVIATIONS 
 
 
RTI  –  Reproductive Tract Infections 
STD  –  Sexually Transmitted Disease 
HIV  –  Human Immunodeficiency Virus 
HBV  –  Hepatitis B Virus 
HCV  –  Hepatitis C Virus 
HSV  –  Herpes Simplex Virus 
HPV  –  Human Papilloma Virus 
TV  –  TrichomonasVaginalis 
BV  –  Bacterial Vaginosis 
PID  –  Pelvic Inflammatory Disease 
RPR  –  Rapid Plasma Reagin 
TPHA  –  TreponemaPallidumHaemagglutination 
ELISA  –  Enzyme Linked ImmunoSorbent Assay 
PCR  –  Polymerase Chain Reaction 
NACO  –  National AIDS Control Organisation 
WHO  –  World Health Organisation 
CDC  –  Centre for Disease Control 
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 APPENDIX 

STAINS AND REAGENTS: 
GRAM STAINING 
 
x Methyl violet  (2%)  -   l0g Methyl violet  in l00ml absolute alcohol in 1litre of 
distilled water (primary stain) 
x Grams Iodine l0g Iodine in 20g KI (fixative) 
x Acetone (Decolourising agent) 
x Carbolfuchsin 1% Secondary stain 
PAPPANICOLAOU STAIN: 
x Ethyl alcohol 80 to 82% 
x Water 9 to 10% 
x Methyl alcohol 4 to 5% 
x Isopropyl alcohol 4 to 5% 
x Eosin- Y <1.0% 
x Phosphotungstic acid <1.0% 
x Fast green <0.1% 
CULTURE MEDIA: 
1.  Mac Conkey agar: 
 Peptone  - 20g 
 Sodium taurocholate-  5g 
 Distilled Water  - 1 ltr 
 Agar -  20g 
 2% neutral red in 50% ethanol -  3.5ml 
 10% lactose solution  - l00ml 
 Dissolve peptone and taurocholate in water by heating. Add agar and 
  dissolve it in steamer. Adjust pH to 7.5. Add lactose and neutral red shake well 
 and mix.Heat in free steam (100°C) for 1 hour, then autoclave at 115°C for 15 
 minutes. 
2.  Blood agar (5% sheep blood agar): 
 Peptone-  l0g 
 NaCl-  5g 
 Distilled water-  1Ltr 
 Agar  - 10g 
 Dissolve ingredients in distilled water by boiling, and add 5% sheep 
 blood(sterile) at 55°C adjust pH to 7.4. 
3.  Modified Thayer Martin Medium: 
Approximate formula per litre 
Pancreatic digest of Casein – 7.5g 
Agar                                      - 12 g 
Selected Meat peptone          - 7.5g 
Hemoglobin                            - 10g 
Corn starch        - 1 g 
IsoVitaleX Enrichment  - 10ml 
Dipotassium phosphate  - 4 g 
V-C-Ninhibitor  - 10ml 
Monopotassium phosphate - 1g 
Trimethoprim lactate   - 5mg 
Sodium chloride  - 5g 
Free water    - 500µl 
 
 4.  Sabouraud’s dextrose agar: 
 Dextrose  - 40g 
 Peptone-  l0g 
 Agar  - 20g 
 Distilled water-  l000ml 
 pH = 5.5 
 Sterilise by autoclaving at 121ºC for 20 min 
5.  Corn Meal Agar: 
Corn meal infusion  - 2gms/litre 
Agar             - 15gms/litre 
Final pH of 6±0.2 at 25°C 
6.  Muller Hinton Agar: 
Beef infusion solids – 4gms/litre 
Starch – 1.5gms/litre 
Casein hydrolysate – 17.5 gms/litre 
Agar – 15gms/litre 
Final pH – 7.4±0.2 
Suspend 38g in 1 litre of distilled water,  bring to the boil  to dissolve the medium 
completely and sterilize by autoclaving at 121°C for 15 minutes. 
  
 MEDIA REQUIRED FOR BIOCHEMICAL IDENTIFICATION: 
1. Oxidase Reagent 
 Tetra methyl p-phenylenediaminedihyrochloride- 1% aqueous solution. 
2. Catalase 
 3% hydrogen peroxide 
3. Indole test 
Kovac’s reagent 
Amyl or isoamyl alcohol 150ml 
Para dimethyl amino benzaldehyde 10g 
Concentrated hydrochloric acid 50ml 
Dissolve the aldehyde in the alcohol and slowly add the acid. Prepare in 
small quantities and store in the refrigerator. Shake gently before use. 
4.  Christensen’s Urease test medium 
Peptone 1g 
Sodium chloride 5g 
Dipotassium hydrogen phosphate 2g 
Phenol red 6ml 
Agar 20g 
Distilled water 1 ltr 
10% sterile solution of glucose l0ml 
Sterile 20% urea solution l00ml 
Sterilize the glucose and urea solutions by filtration. Prepare the basal 
medium without glucose and urea, adjust to pH 6.8-6.9 and sterilize by autoclaving 
in aflask at 121°C for 30min. Cool to about 50°C, add the glucose & urea, and tube 
themedium as slopes. 
 5.  Simmon’s Citrate Medium 
Koser’s medium 1 ltr 
Agar 20g 
Bromothymol blue 0.2% 40ml 
Dispense, autoclave at 121°C for 15 min and allow to set as slopes 
6. Triple Sugar Iron medium 
Beef extract 3g 
Yeast extract 3g 
Peptone 20g 
Glucose 1g 
Lactose l0g 
Sucrose l0g 
Ferric citrate 0.3g 
Sodium chloride 5g 
Sodium thiosulphate 0.3g 
Agar 12g 
Phenol red 0.2% solution l2ml 
Distilled water 1 ltr 
Heat to dissolve the solids, add the indicator solution, mix and tube. 
Sterilize at 121°C for 15 min and cool to form slopes with deep butts. 
7. Peptone water fermentation test medium. 
To the basal medium of peptone water, add sterilised sugars of 1% 
indicator :bromothymol blue with Durham’s tube. 
Basal medium peptone water 
Sugar solutions: 
 Sugar 1ml 
Dislilled water l00ml 
pH = 7.6. 
8. Mannitol motility medium 
Agar 5g 
Peptone 1g 
Potassium nitrate 1g 
Mannitol 2g 
Phenol red indicator 
Distilled water l000ml 
pH 7.2 
9. Hugh &Leifson’s Oxidation –Fermentation test: 
Peptone 2g 
Sodium chloride 5g 
D-glucose 10g 
Bromothymol blue 0.03g 
Agar 3.0g 
Dipotassium phosphate 0.30g 
Distilled water 1L 
pH =7.1 
Basal medium is autoclaved.1% of sterile sugar solutions is added to the 
basal medium.Dispense into sterile test tubes without slant. 
10.  Coagulase test: 
 Fresh human plasma (sterile) 
 
  
  
PATIENT PROFORMA 
NAME: 
 
AGE: 
 
IP/OP NO.: 
 
ADDRESS: 
 
OCCUPATION: 
 
HUSBAND OCCUPATION: 
 
SOCIOECONOMIC STATUS: 
 
SPECIMEN COLLECTED: ENDOCERVICAL SWAB 
                                       VAGINAL SWAB 
      BLOOD – 5 ml 
HISTORY OF PRESENT ILLNESS: 
 
MARITAL HISTORY: 
 
PARITY HISTORY: 
 
MENSTRUAL HISTORY: 
 
STERILISATION HISTORY: 
 
 
PAST HISTORY ( CONTACT HISTORY): 
 
  
 LABORATORY EVALUATION FORM 
 
VAGINAL SWAB: 
 
x MICROSCOPIC EXAMINATION: 
x BACTERIAL CULTURE: 
x FUNGAL CULTURE: 
ENDOCERVICAL SWAB: 
x REAL TIME PCR ASSAY : 
SERUM SAMPLE: 
x SYPHILIS : 
x HBV: 
x HIV : 
x HCV : 
x HSV : 
 
INFERENCE: 
 
  
 PATIENT CONSENT FORM 
 
STUDY DETAIL: 
 
 “MICROBIOLOGICAL PROFILE OF LOWER GENITAL TRACT 
INFECTIONS IN WOMEN OF REPRODUCTIVE AGE GROUP WITH SPECIAL 
REFERENCE TO CHLAMYDIA TRACHOMATIS BY REALTIME PCR ASSAY IN A 
TERTIARY CARE HOSPITAL ”  
 
STUDY CENTER: 
 
 CHENGALPATTU MEDICAL COLLEGE & HOSPITAL, CHENGALPATTU 
 
 
PATIENT NAME:      PATIENT AGE: 
 
IDENTIFICATION NUMBER: 
 
PATIENT TO TICK (        )THESE BOXES  
 
 
 I  confirm that  I  have  understood  the  purpose  of  procedure  for  the  above  study.   I  
have the opportunity to ask the question and all my questions and doubts have been 
answered to my satisfaction.I understand that my participation in the study is voluntary and 
that I am free to withdraw at anytime without giving any reasons, without my legal rights 
being affected.I understand that investigator, regulatory authorities and the ethics 
committee will not need my permission to look at my health records both in respect to the 
current study and any further research that may be conducted in relation to it, even if 
withdraw from the study, I understand that my identity will not be revealed in any 
information released to third parties or published, unless as required under the law. I agree 
not to restrict the use of any data or results that arise from the study. 
 
 I  agree  to  take  part  in  the  above  study  and  to  comply  with  the  instructions  given  
during the study and faithfully cooperative with the study team and to immediately inform 
the study staff if I suffer from any deterioration in my health or wellbeing or any 
unexpected or unusual symptoms. 
 
 I hereby give consent to participate in this study. I hereby give permission to 
undergo complete clinical examination and diagnostic test. 
 
 
Signature/Thumb impression:    Place:    Date: 
Patient name and address: 
 
Signature of the investigator:    Place:    Date: 
Study investigator’s name: 
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 MICROBIOLOGICAL PROFILE OF LOWER GENITAL TRACT 
INFECTIONS IN WOMEN OF REPRODUCTIVE AGE GROUP WITH SPECIAL 
REFERENCE TO CHLAMYDIA TRACHOMATIS BY REALTIME PCR ASSAY 
IN A TERTIARY CARE HOSPITAL  
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Number Age Residence Occupation Spouse O Parity Contracep Discharge Abd pain Itching BM Signs Wetmount DGS Pap Bac cult Fung cult PCR Syphilis HBV HCV HSV HIV
1 21 1 1 3 P1L1 Nil - + + - D - GNB/PC inflammation Kleb.pneumoniae NG Negative NR Negative Negative Positive Negative
2 27 2 2 5 P2L2 PS - + - - D - GPB NILM NG NG Negative NR Negative Negative Negative Negative
3 23 1 1 2 P1L1 Nil + + - - R yeast cells GPBYC NILM NG NG Negative NR Negative Negative Positive Negative
4 24 1 1 2 P2L2A1 Nil + + - - D - - NILM NG NG Negative NR Negative Negative Negative Negative
5 40 1 2 2 P3L3 PS + + - - D - GNB inflammation Escherichia coli NG Negative NR Negative Negative Positive Negative
6 22 1 1 4 P1L1 Nil + - + - D,R yeast cells pseudo candida Escherichia coli C. keyfr Positive NR Positive Negative Positive Positive
7 23 1 1 5 P1L1 Nil + + - - D - GPB, GPC NILM NG NG Negative NR Negative Negative Negative Negative
8 23 2 2 2 P1L1A1 Barrier + - - - Nil - GPB/GPC/PC inflammation Staph.aureus NG Negative NR Negative Negative Negative Negative
9 21 1 1 5 nulli Nil - - + + Nil - - NILM NG NG Negative NR Negative Negative Negative Negative
10 25 1 1 5 P2L2 PS - + - - Nil - GPB NILM NG NG Negative NR Negative Negative Positive Negative
11 20 1 2 5 A1 Nil + - - - D - GPB/PC inflammation Kleb.pneumoniae NG Negative NR Negative Negative Negative Negative
12 24 2 2 2 P1L1A1 IUCD + + - - Nil - GPB NILM NG NG Positive NR Negative Negative Negative Negative
13 25 1 1 5 P2L2 PS - + - + Nil - GPB/GNB inflammation Escherichia coli NG Negative NR Negative Negative Positive Negative
14 23 1 1 3 nulli Nil + + + + D,R motile TV - TV NG NG Negative NR Negative Negative Negative Negative
15 22 1 1 2 nulli Nil + + - - Nil - - NILM NG NG Negative NR Negative Negative Negative Negative
16 33 2 1 3 P2L2 PS + - + - D yeast cells GPBYC NILM NG NG Negative NR Negative Negative Negative Negative
17 28 1 2 5 P2L2 PS + + - - Nil - - NILM NG NG Negative NR Negative Negative Negative Negative
18 22 2 1 2 P1L1 IUCD + - + + D,R yeast cells GPBYC candida NG C. tropicalis Negative NR Negative Negative Negative Negative
19 24 2 1 5 P1L1 Barrier + - - + Nil - GPB NILM NG NG Negative NR Negative Negative Positive Negative
20 22 1 1 2 nulli Nil + - - - Nil - GPB NILM NG NG Negative NR Negative Negative Positive Negative
21 21 1 1 4 P1L1 IUCD + + - - Nil - clue cells, GPC shift in flora NG NG Negative NR Negative Negative Positive Negative
22 20 2 2 5 P1L1 Nil + - - - Nil - GPBYC NILM NG NG Positive NR Negative Negative Positive Negative
23 26 1 1 5 P2L2 PS + - + - D yeast cells GPBYC candida NG C. tropicalis Negative NR Negative Negative Negative Negative
24 21 1 4 5 nulli Nil + - - - Nil - - NILM NG NG Negative NR Negative Negative Negative Negative
25 23 2 1 4 P1L1 IUCD - + - - Nil - - NILM NG NG Negative NR Negative Negative Negative Negative
26 26 1 2 2 P2L2 PS + - + - D - GPBYC NILM NG NG Negative NR Negative Negative Positive Negative
27 23 1 1 3 P1L1 Nil - + - - Nil - - inflammation NG NG Negative NR Negative Negative Negative Negative
28 23 1 1 5 P1L1 Nil + - - - Nil - - NILM NG NG Negative NR Positive Negative Positive Positive
29 23 2 1 3 P2L2 PS - + - - D - PC inflammation Escherichia coli NG Negative NR Negative Negative Negative Negative
30 21 1 1 3 P1L1 Nil + + - - Nil - - NILM NG NG Negative NR Negative Negative Negative Negative
31 20 1 1 5 A1 Nil + + - - D - GNB/PC inflammation Citrobacter koseri NG Positive NR Negative Negative Positive Negative
32 23 1 1 3 P1L1A1 Nil + + + - D,R yeast cells GPBYC candida NG C. albicans Negative NR Negative Negative Negative Negative
33 30 1 2 2 P2L2 PS - + + - D,nodule - - NILM NG NG Negative NR Negative Negative Negative Negative
34 20 1 1 3 P1L1 Nil + + - - D - GPBYC candida Escherichia coli C. keyfr Negative NR Negative Negative Positive Negative
35 23 2 1 5 P1L1A1 IUCD + - + + D yeast cells GPBYC candida NG C. albicans Negative NR Negative Negative Negative Negative
36 27 1 2 3 P2L2 PS - + - - Nil - - NILM NG NG Negative Reactive Negative Negative Positive Negative
37 21 1 1 4 nulli Nil + + - - Nil - - NILM NG NG Negative NR Negative Negative Negative Negative
38 25 1 1 3 P2L2 PS - + - - Nil - GPB NILM NG NG Negative NR Negative Negative Negative Negative
39 40 1 1 5 P3L3 PS + - - + D - GPB/GNB inflammation Escherichia coli NG Negative NR Negative Negative Negative Negative
40 24 1 1 5 P2L2 PS + + - - Nil - - NILM NG NG Negative NR Negative Negative Positive Negative
41 24 1 1 3 P2L2 PS - + - - Nil - - NILM NG NG Negative NR Negative Negative Negative Negative
42 26 1 1 3 P2L2 PS + + - - D - GPB NILM NG NG Positive NR Negative Negative Negative Negative
43 21 2 1 3 nulli Nil + + + - D,R yeast cells GPBYC candida NG C. albicans Negative NR Negative Negative Positive Negative
44 32 2 1 4 P3L3 PS - + - - Erosion - GPC NILM NG NG Negative NR Negative Negative Negative Negative
45 38 1 1 5 P2L2 PS + + - - Nil - - NILM NG NG Negative NR Negative Negative Negative Negative
46 40 1 1 3 P3L3 PS + - - - Nil - - NILM NG NG Negative NR Negative Negative Negative Negative
47 27 1 1 4 P4L1 PS + + - - D - - NILM NG NG Negative NR Negative Negative Negative Negative
48 32 1 1 2 P2L2 PS - + - - R - GPB NILM NG NG Negative NR Negative Negative Negative Negative
49 36 1 1 3 P3L3 PS + + - - D pus cells GPC/PC inflammation Streptococcal Sp., NG Negative NR Negative Negative Negative Negative
50 40 1 1 3 P3L3 PS + - + - D,R yeast cells GPBYC candida NG C. tropicalis Negative NR Negative Negative Positive Negative
51 35 1 1 4 P2L2 PS - + - - Nil - - inflammation Kleb.pneumoniae NG Negative NR Negative Negative Negative Negative
52 34 1 1 2 P2L2 PS - + - - Nil - - NILM NG NG Negative NR Negative Negative Negative Negative
53 26 1 1 3 P2L2 PS + - - - D - - NILM NG NG Negative NR Negative Negative Negative Negative
54 24 2 1 2 P1L1 IUCD - + - - D pus cells - inflammation Kleb.pneumoniae NG Negative NR Negative Negative Negative Negative
55 25 1 6 6 nulli Nil + - + - D,R yeast cells GPBYC/PC/GPC candida Staph.aureus C. albicans Negative NR Negative Negative Negative Negative
56 40 1 2 2 P3L3 PS + + - - D - - NILM NG NG Negative NR Negative Negative Negative Negative
57 21 1 1 4 P1L1 Nil + + - - Nil - - NILM NG NG Negative NR Negative Negative Negative Negative
58 24 1 1 5 P2L2 PS + + - - Nil - - NILM NG NG Negative NR Negative Negative Negative Negative
59 26 2 3 5 P2L2A1 PS - + - - Nil - - NILM NG NG Negative NR Negative Negative Negative Negative
60 24 1 6 5 P2L2 PS + - + - D,R yeast cells GPBYC candida NG C. albicans Negative NR Negative Negative Positive Negative
61 27 1 2 2 P2L2 PS - + - + Nodule - - NILM NG NG Negative NR Negative Negative Negative Negative
62 21 1 1 5 P1L0 Nil + + + - D,R - clue cells, GPC shift in flora NG NG Negative NR Negative Negative Negative Negative
63 26 2 2 4 P1L1 IUCD + + - - Nil - GPBYC NILM NG NG Negative NR Negative Negative Negative Negative
64 30 1 1 5 P2L2 PS + + - - Erosion - - NILM NG NG Positive NR Negative Negative Positive Negative
65 22 1 1 2 nulli Nil + - - - Nil - - NILM NG NG Negative NR Negative Negative Negative Negative
66 22 1 1 4 P1L1 Nil + - - - D - GPB NILM NG NG Negative NR Negative Negative Negative Negative
67 32 2 2 5 P1L1 IUCD + - + - D,R yeast cells GPBYC candida NG C. glabrata Negative NR Negative Negative Negative Negative
68 22 1 1 2 P1L1 Nil + - - - Nil - - NILM NG NG Negative NR Negative Negative Negative Negative
69 24 1 5 5 nulli Nil + + + - D,erosions yeast cells clue cells, GPBYC inflammation Escherichia coli C. albicans Negative NR Negative Negative Negative Negative
70 34 2 1 5 P2L2 PS + - - + D - - NILM NG NG Negative NR Negative Negative Negative Negative
71 29 1 1 5 P2L2 PS + + - - Nil - GPB NILM NG NG Negative NR Negative Negative Negative Negative
72 31 1 1 3 P2L2 PS + + - - D pus cells GPB/PC inflammation Escherichia coli NG Negative NR Negative Negative Negative Negative
73 24 2 1 4 P1L1 Barrier - + - - D - - NILM NG NG Negative NR Negative Negative Negative Negative
74 43 1 1 3 P2L2 PS + + - - Nil - GPB NILM NG NG Negative NR Negative Negative Positive Negative
75 25 2 1 3 P1L1A1 IUCD + - - + D yeast cells GPBYC candida NG C. glabrata Positive NR Negative Negative Negative Negative
76 33 1 1 3 P3L2 PS + + - - D,R motile TV GPBYC TV NG NG Negative NR Negative Negative Positive Negative
77 29 1 2 2 P2L2 PS + - - + Nil - - NILM NG NG Negative NR Negative Negative Negative Negative
78 26 1 2 2 P2L2 PS + - + - D pus cells GPC NILM NG NG Negative NR Negative Negative Negative Negative
79 27 1 2 4 P3L2 PS - + - - R - GPB,GPBYC NILM NG NG Negative NR Negative Negative Negative Negative
80 28 1 3 3 P2L2 PS + - - - D - GPB NILM NG NG Negative NR Negative Negative Negative Negative
81 25 1 2 3 P2L2 PS + - + - D,erosions yeast cells GPBYC candida NG C. glabrata Negative NR Negative Negative Positive Negative
82 25 2 1 2 P1L1 Nil + - - - D - - NILM NG NG Negative NR Negative Negative Negative Negative
83 42 1 2 3 P2L2 PS + - - - Nil - - NILM NG NG Negative NR Negative Negative Negative Negative
84 27 1 1 3 P2L2 PS - + - + D - - NILM NG NG Positive NR Negative Negative Negative Negative
85 28 1 2 3 P2L2 PS + - - - D pus cells GPBYC/PC inflammation Escherichia coli NG Negative NR Negative Negative Negative Negative
86 28 1 1 2 P2L2 PS + - - - R - - NILM NG NG Negative NR Negative Negative Negative Negative
87 25 2 1 3 P1L1 Nil - + - - Nil - GPB NILM NG NG Negative NR Positive Negative Positive Positive
88 26 1 1 5 P1L1 Nil + - + - D - - NILM NG NG Negative NR Negative Negative Negative Negative
89 26 1 2 2 P2L2 PS + - - - Erosion - clue cells shift in flora NG NG Negative NR Negative Negative Positive Negative
90 27 1 2 3 P2L2 PS + - - - R - GPB NILM NG NG Negative NR Negative Negative Negative Negative
91 26 2 2 2 P1L1 IUCD + - + + D,R yeast cells GPBYC candida NG C. albicans Negative NR Negative Negative Negative Negative
92 28 1 1 4 P2L2 PS + - - - Nil - - NILM NG NG Negative NR Negative Negative Negative Negative
93 28 1 2 2 P2L2 PS + - - - D - - NILM NG NG Negative NR Negative Negative Negative Negative
94 28 1 1 3 P2L2 PS - + - + D - GPBYC NILM NG NG Negative NR Negative Negative Negative Negative
95 25 2 3 3 P1L1 Nil + - - - D - - NILM NG NG Negative NR Negative Negative Negative Negative
96 25 1 1 5 P2L2 PS + - - - D motile TV - TV NG NG Negative NR Negative Negative Positive Negative
97 26 1 2 2 P2L2 PS - + - + Nil - - NILM NG NG Negative NR Negative Negative Negative Negative
98 26 1 1 3 P2L2 PS + + - + D - PC inflammation Kleb.pneumoniae NG Positive NR Negative Negative Negative Negative
99 30 1 1 4 P2L2 PS + - - - D - - NILM NG NG Negative NR Negative Negative Negative Negative
100 36 1 1 3 P3L3 PS + + + + D,erosions yeast cells GPBYC candida NG C. keyfr Negative NR Negative Negative Positive Negative
101 28 1 2 2 P2L2 PS + + - - D - - NILM NG NG Negative NR Negative Negative Negative Negative
102 29 1 1 2 P2L2 PS - - + - Nil - GPB NILM NG NG Negative NR Negative Negative Negative Negative
103 32 1 2 2 P3L3 PS + - - - D - - NILM NG NG Negative NR Negative Negative Negative Negative
104 33 2 1 4 P2L1 IUCD + - + - D yeast cells GPBYC inflammation Escherichia coli NG Negative NR Negative Negative Negative Negative
105 25 2 1 4 P1L1 IUCD - + - + Nil - - NILM NG NG Negative NR Negative Negative Negative Negative
106 27 1 1 5 P2L2 PS + - - - D yeast cells GPBYC NILM NG C. albicans Negative NR Negative Negative Negative Negative
107 26 1 2 3 P3L2 PS + + - - D - - NILM NG NG Negative NR Negative Negative Negative Negative
108 27 1 1 4 P2L2 PS + + - - D - - NILM NG NG Negative NR Negative Negative Negative Negative
109 25 2 2 5 P2L1 Barrier + - - - D - - NILM NG NG Negative NR Negative Negative Negative Negative
110 29 1 1 4 P2L2 PS - + + + Nil - - NILM NG NG Negative NR Negative Negative Positive Negative
